<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Transl Med</journal-id><journal-id journal-id-type="iso-abbrev">J Transl Med</journal-id><journal-id journal-id-type="pmc-domain-id">214</journal-id><journal-id journal-id-type="pmc-domain">transmed</journal-id><journal-title-group><journal-title>Journal of Translational Medicine</journal-title></journal-title-group><issn pub-type="epub">1479-5876</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11293007</article-id><article-id pub-id-type="pmcid-ver">PMC11293007.1</article-id><article-id pub-id-type="pmcaid">11293007</article-id><article-id pub-id-type="pmcaiid">11293007</article-id><article-id pub-id-type="pmid">39085889</article-id><article-id pub-id-type="doi">10.1186/s12967-024-05538-4</article-id><article-id pub-id-type="publisher-id">5538</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Clinical implications of the family history in patients with lung cancer: a systematic review of the literature and a new cross-sectional/prospective study design (FAHIC: lung)</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Citarella</surname><given-names initials="F">Fabrizio</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Takada</surname><given-names initials="K">Kazuki</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cascetta</surname><given-names initials="P">Priscilla</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Crucitti</surname><given-names initials="P">Pierfilippo</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Petti</surname><given-names initials="R">Roberta</given-names></name><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vincenzi</surname><given-names initials="B">Bruno</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tonini</surname><given-names initials="G">Giuseppe</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Venanzi</surname><given-names initials="FM">Francesco M.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bulotta</surname><given-names initials="A">Alessandra</given-names></name><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Oresti</surname><given-names initials="S">Sara</given-names></name><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Greco</surname><given-names initials="C">Carlo</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ramella</surname><given-names initials="S">Sara</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Crin&#242;</surname><given-names initials="L">Lucio</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Delmonte</surname><given-names initials="A">Angelo</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ferrara</surname><given-names initials="R">Roberto</given-names></name><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Di Maio</surname><given-names initials="M">Massimo</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gurrieri</surname><given-names initials="F">Fiorella</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1209-5735</contrib-id><name name-style="western"><surname>Cortellini</surname><given-names initials="A">Alessio</given-names></name><address><email>a.cortellini@policlinicocampus.it</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff12">12</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.488514.4</institution-id><institution-id institution-id-type="ISNI">0000000417684285</institution-id><institution>Operative Research Unit of Medical Oncology, </institution><institution>Fondazione Policlinico Universitario Campus Bio-Medico, </institution></institution-wrap>Via Alvaro del Portillo, 200, 00128 Rome, Italy </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.9657.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 5329</institution-id><institution>Department of Medicine and Surgery, </institution><institution>Universit&#225; Campus Bio-Medico Di Roma, </institution></institution-wrap>Via Alvaro del Portillo, 21, 00128 Rome, Italy </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05c8e3213</institution-id><institution-id institution-id-type="GRID">grid.416599.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 1774 2406</institution-id><institution>Department of Surgery, </institution><institution>Saiseikai Fukuoka General Hospital, </institution></institution-wrap>Fukuoka, Japan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.14925.3b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2284 9388</institution-id><institution>Department of Cancer Medicine, </institution><institution>Gustave Roussy Cancer Campus, </institution></institution-wrap>Villejuif, France </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.488514.4</institution-id><institution-id institution-id-type="ISNI">0000000417684285</institution-id><institution>Thoracic Surgery Department, </institution><institution>Fondazione Policlinico Universitario Campus Bio-Medico, </institution></institution-wrap>Via Alvaro del Portillo 200, 00128 Rome, Italy </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.488514.4</institution-id><institution-id institution-id-type="ISNI">0000000417684285</institution-id><institution>Operative Research Unit of Medical Genetics, </institution><institution>Fondazione Policlinico Universitario Campus Bio-Medico, </institution></institution-wrap>Via Alvaro del Portillo, 21, 00128 Rome, Italy </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01gmqr298</institution-id><institution-id institution-id-type="GRID">grid.15496.3f</institution-id><institution-id institution-id-type="ISNI">0000 0001 0439 0892</institution-id><institution>Universit&#224; Vita-Salute San Raffaele, </institution></institution-wrap>Milan, Italy </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/039zxt351</institution-id><institution-id institution-id-type="GRID">grid.18887.3e</institution-id><institution-id institution-id-type="ISNI">0000 0004 1758 1884</institution-id><institution>Department of Medical Oncology, </institution><institution>IRCCS Ospedale San Raffaele, </institution></institution-wrap>Milan, Italy </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.488514.4</institution-id><institution-id institution-id-type="ISNI">0000000417684285</institution-id><institution>Radiation Oncology, </institution><institution>Fondazione Policlinico Universitario Campus Bio-Medico, </institution></institution-wrap>Via Alvaro del Portillo, 200, 00128 Rome, Italy </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.419563.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 1755 9177</institution-id><institution>Thoracic Oncology Unit, </institution><institution>IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) &#8220;Dino Amadori&#8221;, </institution></institution-wrap>Meldola, Italy </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/048tbm396</institution-id><institution-id institution-id-type="GRID">grid.7605.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2336 6580</institution-id><institution>Department of Oncology, Medical Oncology 1U, AOU Citt&#224; della Salute e della Scienza di Torino, </institution><institution>University of Turin, </institution></institution-wrap>10126 Turin, Italy </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/041kmwe10</institution-id><institution-id institution-id-type="GRID">grid.7445.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 2113 8111</institution-id><institution>Department of Surgery and Cancer, </institution><institution>Hammersmith Hospital Campus, Imperial College London, </institution></institution-wrap>London, UK </aff></contrib-group><pub-date pub-type="epub"><day>31</day><month>7</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>22</volume><issue-id pub-id-type="pmc-issue-id">452086</issue-id><elocation-id>714</elocation-id><history><date date-type="received"><day>2</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>24</day><month>7</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>31</day><month>07</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>01</day><month>08</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-08-28 13:25:29.907"><day>28</day><month>08</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12967_2024_Article_5538.pdf"/><abstract id="Abs1"><p id="Par1">Compared to other malignancies, few studies have investigated the role of family history of cancer (FHC) in patients with lung cancer, yielding largely heterogeneous results. We performed a systematic literature review in accordance with PRISMA guidelines, searching the PubMed and Scopus databases from their inception to November 25, 2023, to identify studies reporting on the role of FHC in patients with lung cancer. A total of 53 articles were included, most with a retrospective design and encompassing a variety of geographical areas and ethnicities.</p><p id="Par2">Thirty studies (56.6%) assessed patients with non-small cell lung cancer (NSCLC), while 17 studies (32.1%) assessed patients with mixed histologies. Overall, the rates of FHC ranged from 8.3 to 68.9%, and the rates of family history of lung cancer ranged from 2 to 46.8%. Twenty-seven studies investigated FHC as a potential risk factor for lung cancer, with more than half reporting an increased risk for subjects with FHC. Five studies reported on the potential role of FHC in determining clinical outcomes, and twelve studies examined the relationship between FHC and germline mutations. Notably, only one study reported a significantly increased rate of germline mutations, including <italic toggle="yes">ATM</italic>, <italic toggle="yes">BRCA2</italic>, and <italic toggle="yes">TP53</italic>, for patients with a family history of lung cancer compared to those without, but both groups had a low prevalence of mutations (&lt;&#8201;1%).</p><p id="Par3">The FAHIC&#8212;Lung (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06196424">NCT06196424</ext-link>) is the first cross-sectional/prospective study specifically developed to identify FHC patterns and within-family clusters of other risk factors, including smoking, to guide patients with NSCLC to systematic genetic counseling. Acknowledging the largely heterogeneous results of our systematic review and considering the clinical implications of detecting pathogenic germline variants (PGVs), the FAHIC-lung study aims to identify patients potentially enriched with PGVs/likely PGVs to direct them to germline screening outside of the research setting.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12967-024-05538-4.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Lung cancer</kwd><kwd>NSCLC</kwd><kwd>Family history of cancer</kwd><kwd>Germline screening</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par4">Familial aggregation and inherited predisposition have been increasingly investigated in multiple cancer types. In breast, ovarian, prostate, and colorectal malignancies, international guidelines recommend genetic counselling in patients showing risk criteria for syndromes of inherited susceptibility to cancer, as aggregations with other malignancies have been widely described within families of these patient populations [<xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par5">With a predicted number of death of about 160 000 cases in 2023 in Europe and 127 070 in US [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>], Non-Small Cell Lung Cancer (NSCLC) still remains a leading cause of cancer death worldwide. A positive smoking history represents the main risk factor [<xref ref-type="bibr" rid="CR6">6</xref>], while environmental factors such as exposure to radon, asbestosis and air pollution have been linked to lung cancer among never smokers [<xref ref-type="bibr" rid="CR7">7</xref>&#8211;<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par6">Few studies have investigated the impact of a positive family history of cancer (FHC) in patients with NSCLC, describing the malignancies that can occur among relatives of patients with NSCLC, while only few and rare genetic syndromes associated with inherited germline genetic mutations, such as the Li-Fraumeni, have been directly linked to lung cancer risk [<xref ref-type="bibr" rid="CR10">10</xref>]. Most of the studies did not provide information on the potential within-family clusters of other risk factors, including exposure to tobacco smoking, environmental carcinogens, and other geographical/epidemiological factors. Additionally, retrospective approaches to this topic are heavily impacted by recall bias and misclassification [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par7">To underline the importance and potential clinical implications of investigating family history of cancer (FHC) in patients with non-small cell lung cancer (NSCLC), a recent retrospective study conducted in a cohort of 7.788 patients with NSCLC, who underwent commercially available germline genetic testing and reported an FHC of 71%, found that pathogenic germline variants (PGVs) or likely PGVs were present in 14.9% of the cases. Additionally, 2.9% of the cases carried a single PGV in a gene associated with autosomal recessive inheritance. Among positive patients, 61.3% carried a PGV/likely PGV in DNA damage and response (DDR) genes, and 95.1% of them harbored a PGV in genes with potential clinical implications, including <italic toggle="yes">BRCA2</italic> (2.8%), <italic toggle="yes">CHEK2</italic> (2.1%), <italic toggle="yes">ATM</italic> (1.9%), <italic toggle="yes">TP53</italic> (1.3%), <italic toggle="yes">BRCA1</italic> (1.2%), and <italic toggle="yes">EGFR</italic> (1.0%) [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par8">In this manuscript, we present the results of a systematic review of the available evidence on the role of FHC in patients with lung cancer, and the design of the FAHIC-lung study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06196424">NCT06196424</ext-link>), a cross-sectional study that aims to prospectively describe the FHC and the potential within-family distribution of smoking and other risk factors, to identify patients more likely to be carriers of PGVs or likely PGVs.</p></sec><sec id="Sec2"><title>Systematic review&#8212;methods</title><sec id="Sec3"><title>Literature search strategy and study selection criteria</title><p id="Par9">This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We searched the PubMed and Scopus databases from their inception date to November 25, 2023, to identify potentially relevant articles. The search terms were &#8220;non-small cell lung cancer or NSCLC,&#8221; &#8220;family history,&#8221; &#8220;lung cancer,&#8221; and &#8220;risk.&#8221;</p><p id="Par10">The inclusion criteria for the study selection were as follows: (1) patients diagnosed with NSCLC of any stage; (2) available information on the family history of cancer for the included population (e.g., prevalence and type of family history). The exclusion criteria were as follows: (1) lack of information on the family history of cancer; (2) studies not published in English; and (3) case reports.</p><p id="Par11">As this study was a systematic review, ethical approval and informed consent were not required. The study protocol was registered in PROSPERO, an international prospective register of systematic reviews funded by the National Institute for Health Research (NIHR), with the registration code CRD4202450742 (available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024507422">https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024507422</ext-link>).</p></sec><sec id="Sec4"><title>Data extraction and data synthesis</title><p id="Par12">Two authors (F.C. and K.T.) performed the literature search and evaluated the eligibility of studies using the PICO (patients, interventions, comparison, and outcome) framework following the PRISMA criteria. Assuming a certain heterogeneity in the results, we adopted a textual narrative synthesis approach to summarize the included publications [<xref ref-type="bibr" rid="CR14">14</xref>]. In view of that, we did not establish specific criteria for data synthesis (e.g., the minimum number of studies or level of consistency required for synthesis).</p><p id="Par13">F.C. and T.K. independently reviewed and extracted data from the published papers, including first author, journal name, and year of publication. The prevalence (as a rate) of family history of cancer was summarized in a master table, along with the type of family history collected (e.g., lung-cancer specific vs. family history of any malignancy), study design, study population characteristics, smoking status of study participants and screened relatives (if available), primary tumor type (e.g., NSCLC, small cell lung cancer [SCLC], or others), number of patients included, and disease stage (e.g., early stage vs. advanced stage, if available). Study characteristics, context, and findings were summarized, and similarities/differences across studies were described in detail. Disagreements between the two authors (F.C. and K.T.) were discussed and resolved with a third independent author (A.C.).</p></sec></sec><sec id="Sec5"><title>Systematic review&#8212;results</title><p id="Par14">We identified a total of 198 potentially relevant articles from the PubMed and Scopus online databases through an initial search strategy. After excluding 41 duplicate articles, we screened and reviewed the titles and abstracts of 157 articles, resulting in 54 being assessed for eligibility. Finally, a total of 53 articles were included in this systematic review. The flow diagram of the study selection process is shown in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref> while the whole search strategy with publications assessed at each step (identification, screening, eligibility and inclusion) is available as supplementary material (search strategy).<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Flow diagram of the studies selection process according to the PRISMA guidelines</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="12967_2024_5538_Fig1_HTML.jpg"/></fig></p><p id="Par15">Overall, the vast majority of the studies had a retrospective design, with most of them being case&#8211;control or observational retrospective studies, with only one cross-sectional study [<xref ref-type="bibr" rid="CR15">15</xref>] and one prospective study [<xref ref-type="bibr" rid="CR16">16</xref>]. Study populations encompassed a variety of geographical areas/ethnicities, with 23 studies (43.4%) enrolling Asian patients, 13 studies (24.5%) enrolling patients with multiple ethnicities (all with a majority of white patients), 11 studies (20.7%) including non-specified ethnicities, and six studies (11.3%) including other populations. Even the included histology types showed heterogeneity, with 30 studies (56.6%) assessing patients with NSCLC, 17 studies (32.1%) assessing patients with a mixed type of lung cancer including small cell lung cancer (SCLC), four studies (7.5%) assessing other/unspecified types of lung cancer, one study (1.9%) assessing patients with adenocarcinoma, and one study (1.9%) assessing patients with <italic toggle="yes">EGFR</italic>-positive adenocarcinoma only.</p><p id="Par16">FHC was collected through questionnaires in only three studies [<xref ref-type="bibr" rid="CR17">17</xref>&#8211;<xref ref-type="bibr" rid="CR19">19</xref>], while none of them used ad-hoc questionnaires specifically developed to collect FHC and the within-family distribution of other risk factors, including smoking. Twenty-five studies (47.2%) assessed family history (FH) by collecting all malignancies reported among relatives, 21 studies (39.6%) assessed FH of lung cancer, three studies (5.7%) assessed FHC and FH of lung cancer separately, three studies (5.7%) assessed FH of smoking-related and smoking-unrelated cancers, and two studies (3.8%) assessed FH of pre-specified types of cancer. The degree of relatedness ranged from first to second degree, although it was not reported for the majority of the included studies. One study reported on the smoking status among the relatives of study participants [<xref ref-type="bibr" rid="CR20">20</xref>] and one study included the assessment of environmental factors (coal exposure) among the risk factors for lung cancer [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par17">Overall, the rate of FHC in patients with lung cancer ranged from 8.3 [<xref ref-type="bibr" rid="CR22">22</xref>] to 68.9% [<xref ref-type="bibr" rid="CR20">20</xref>], while the rates of FH of lung cancer from 2 [<xref ref-type="bibr" rid="CR23">23</xref>] to 46.8% [<xref ref-type="bibr" rid="CR21">21</xref>]. Some studies enrolled cohorts of patients potentially enriched for FHC, such as 11 studies which assessed female patients only reporting FHC ranging from 7.7 [<xref ref-type="bibr" rid="CR24">24</xref>] to 59.4% [<xref ref-type="bibr" rid="CR25">25</xref>] and FH of lung cancer ranging from 6.2 [<xref ref-type="bibr" rid="CR26">26</xref>] to 28% [<xref ref-type="bibr" rid="CR27">27</xref>], four studies which specifically assessed never/light smoker patients only, reporting FHC ranging from 29.1 [<xref ref-type="bibr" rid="CR28">28</xref>] to 68.9 [<xref ref-type="bibr" rid="CR20">20</xref>], two studies assessing patients with small aggressive NSCLC, one study assessing male patients only, one study assessing smokers specifically, and one study assessing patients aged&#8201;&#8804;&#8201;45&#160;years. A synoptic table with organization of results is available as supplementary file 1.</p><sec id="Sec6"><title>Studies investigating FHC as a risk factor for lung cancer</title><p id="Par18">Overall, 27 studies investigated FHC as a potential risk factor for lung cancer (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR23">23</xref>&#8211;<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR29">29</xref>&#8211;<xref ref-type="bibr" rid="CR47">47</xref>]. Six out of 11 studies (54.5%) that investigated the role of FHC as a whole or in pre-specified type of cancers reported an increased risk of developing lung cancer for patients with FHC, while 11 out of 16 studies (68.7%) that investigated the role of FH of lung cancer reported a significant association.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>summary of the included studies reporting on the potential role of FHC as a risk factor for lung cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Study</th><th align="left" colspan="1" rowspan="1">Design</th><th align="left" colspan="1" rowspan="1">Country/Race</th><th align="left" colspan="1" rowspan="1">Study Population</th><th align="left" colspan="1" rowspan="1">Histology</th><th align="left" colspan="1" rowspan="1">Type of FHC</th><th align="left" colspan="1" rowspan="1">Prevalence of FHC among cases</th><th align="left" colspan="1" rowspan="1">Smoking status details (cases)</th><th align="left" colspan="1" rowspan="1">Main findings</th><th align="left" colspan="1" rowspan="1">Additional findings</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Tsugane et al Jpn J Clin Oncol (1987)</td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1">Japan/Asian</td><td align="left" colspan="1" rowspan="1">185 patients with lung cancer diagnosis between 30 and 49&#160;years; 134 matched controls</td><td align="left" colspan="1" rowspan="1">NSCLC, SCLC and others</td><td align="left" colspan="1" rowspan="1">Any cancer (up to second-degree relatives)</td><td align="left" colspan="1" rowspan="1"><p>FHC 36% and 32% for male and female patients with adenocarcinoma respectively FH of lung cancer of 6% and 2% for male and female patients with adenocarcinoma respectively</p><p>FHC of 30% and FH of lung cancer of 5% among patients with squamous cell carcinoma</p></td><td align="left" colspan="1" rowspan="1"><p>Adenocarcinoma histology: 75% male patients were ever smokers,15% of female patients were ever smokers</p><p>&#8201;&gt;&#8201;90% of patients with other tumors were ever smokers</p></td><td align="left" colspan="1" rowspan="1">FHC was not associated with diagnosis of early onset lung cancer</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Osann</p><p>Cancer Res (1991)</p></td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1"><p>USA (86%</p><p>White, 11% black, and 3% Asian)</p></td><td align="left" colspan="1" rowspan="1">217 females diagnosed with lung cancer; 217 matched controls</td><td align="left" colspan="1" rowspan="1">NSCLC, SCLC and others</td><td align="left" colspan="1" rowspan="1">Any cancer categorized as smoking related and smoking unrelated tumors (first-degree relatives)</td><td align="left" colspan="1" rowspan="1">FHC of 22.6% and 45.2% among never and ever smokers. FH of lung cancer of 3.2% and 9.0% among never and ever smokers</td><td align="left" colspan="1" rowspan="1">84.8% of ever smokers</td><td align="left" colspan="1" rowspan="1">FHC was significantly associated with diagnosis of lung cancer (OR 1.8, 95% CI 1.0&#8211;3.2)</td><td align="left" colspan="1" rowspan="1"><p>Stronger association in women aged&#8201;&#8804;&#8201;55 (OR 3.8, 95% CI 0.9&#8211; 16.2) than those aged&#8201;&gt;&#8201;55&#160;years (OR 1.4, 95% CI 0.7&#8211;2.6)</p><p>Smoking and FHC showed synergistic effect in increasing risk of lung cancer</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Gorlova et al Int J Cancer (2006)</td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1">USA/White (82.5%), Hispanic (8.9%), Black (8.6%)</td><td align="left" colspan="1" rowspan="1">280 cases of lung cancer in never/light smokers (&lt;&#8201;100 cigarettes in lifetime); 242 unmatched healthy controls</td><td align="left" colspan="1" rowspan="1">NSCLC, SCLC and others</td><td align="left" colspan="1" rowspan="1">Any cancer, any smoking-related cancer (lung, head and neck, kidney, bladder and pancreatic), lung cancer, lung cancer in at least 1 never-smoker relative, any cancer detected before 50&#160;years</td><td align="left" colspan="1" rowspan="1">FHC of 68.9%, FH of smoking-related cancer of 20.8%, FH of lung cancer of 13.2%, FH of lung cancer in at least one never smokers of 2.3%; FH of any cancer among relatives aged&#8201;&lt;&#8201;50&#160;years 31.5%</td><td align="left" colspan="1" rowspan="1">All cases were never smokers (&lt;&#8201;100 cigarettes in lifetime)</td><td align="left" colspan="1" rowspan="1">No significant association between overall FHC, FH of smoking-related cancers, and FH of lung cancer, and diagnosis of lung cancer</td><td align="left" colspan="1" rowspan="1">FH of any caner among relatives aged&#8201;&lt;&#8201;50&#160;years was associated with the diagnosis of lung cancer (OR 1.87, 95% CI 1.13&#8211;3.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">Chen et al Cancer (2007)</td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1">Taiwan/Asian</td><td align="left" colspan="1" rowspan="1">826 female patients with lung cancer and 531 unmatched heathy controls</td><td align="left" colspan="1" rowspan="1">NSCLC, SCLC and others</td><td align="left" colspan="1" rowspan="1">Breast, ovarian, cervical, and endometrial cancers (first-degree relatives)</td><td align="left" colspan="1" rowspan="1">FHC (breast, ovarian, cervical and endometrial) 7.7%</td><td align="left" colspan="1" rowspan="1">7.1% of ever smokers 69.5% of patients were exposed to passive smoking</td><td align="left" colspan="1" rowspan="1">No difference in FHC between cases and controls</td><td align="left" colspan="1" rowspan="1">Association between Hormone Replacement Therapy (HRT) and reduced risk of lung cancer among patients with negative FHC (OR 0.69, 95% CI 0.51&#8211;0.95)</td></tr><tr><td align="left" colspan="1" rowspan="1">Schwartz et al J Clin Oncol (2007)</td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1">USA/White (77%), Black (23%)</td><td align="left" colspan="1" rowspan="1">488 women with NSCLC; 498 matched controls</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Lung cancer (first-degree relatives)</td><td align="left" colspan="1" rowspan="1">FH of lung cancer of 25%</td><td align="left" colspan="1" rowspan="1">8% of never smokers, 32% of former smokers, 60% of current smokers</td><td align="left" colspan="1" rowspan="1">FH of lung cancer was significantly associated with diagnosis of NSCLC (p&#8201;&lt;&#8201;0.001)</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Tammemagi et al Cancer Epidemiol Biomarkers Prev (2007)</td><td align="left" colspan="1" rowspan="1">Observational, retrospective Case-case study</td><td align="left" colspan="1" rowspan="1">Canada/White (87.5%), Black (4.2%), Hispanic (2.1%), Asian (6.3%)</td><td align="left" colspan="1" rowspan="1">48 cases with Small Aggressive NSCLC (SA-NSCLC) and 329 controls enrolled in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO)</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Lung cancer (first-degree relatives)</td><td align="left" colspan="1" rowspan="1">FH of lung cancer of 26.1%</td><td align="left" colspan="1" rowspan="1">10.4% of never smokers, 52.1% of former smokers, 37.5% of current smokers</td><td align="left" colspan="1" rowspan="1">FH of lung cancer was not associated with diagnosis of SA-NSCLC</td><td align="left" colspan="1" rowspan="1">In patients with FH of lung cancer diagnosis of SA-NSCLC was significantly more frequent among females</td></tr><tr><td align="left" colspan="1" rowspan="1">Cassidy et al Eur J Cancer (2009)</td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1">Europe/not available</td><td align="left" colspan="1" rowspan="1">733 surgically resected patients; 1312 matched controls</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Any cancer, lung cancer, smoking-related cancers, and gastric cancer (first-degree relatives)</td><td align="left" colspan="1" rowspan="1">FH of any cancer 51.5%, FH of lung cancer 18.9%</td><td align="left" colspan="1" rowspan="1">7.1% of never smokers, 75.4% of former smokers, 17.5% of current smokers</td><td align="left" colspan="1" rowspan="1">FH for any cancer significantly associated with diagnosis of risk of NSCLC (OR 1.16, 95%: 1.02&#8211;1.33)</td><td align="left" colspan="1" rowspan="1"><p>FH of lung cancer, FH of smoking-related cancers, and FH of non-smoking related cancers not associated with diagnosis of NSCLC</p><p>Significant association between FH of gastric cancer and diagnosis of NSCLC, between FH of gastric cancer and late-onset NSCLC (&#8805;&#8201;55 years), and between</p><p>FH of lung cancer and diagnosis of early-onset NSCLC (&lt;&#8201;55 years)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Cote et al Carcinogenesis (2009)</td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1">USA/White (48.9%), Black (48.7%)</td><td align="left" colspan="1" rowspan="1">504 female patients with NSCLC; 527 matched controls</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Lung cancer (first-degree relatives)</td><td align="left" colspan="1" rowspan="1">FH of lung cancer of 25.8%</td><td align="left" colspan="1" rowspan="1">7.9% of never smokers, 31.6% of former-smokers, 60.5% of current smokers</td><td align="left" colspan="1" rowspan="1">FH of lung cancer associated with diagnosis of NSCLC in both white and black patients (p&#8201;&lt;&#8201;0.01)</td><td align="left" colspan="1" rowspan="1">FH of lung cancer was among the factors in the most parsimonious model able to predict risk of NSCLC in white ever-smoker women together with age at diagnosis, history of chronic obstructive lung disease, pack-years of cigarette smoking, BMI, XRCC1 A/A genotypes, GSTM1 null and COMT A/G or G/G phenotype</td></tr><tr><td align="left" colspan="1" rowspan="1">Hong et al J Prev Med Public Health (2011)</td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1">Korea/Asian</td><td align="left" colspan="1" rowspan="1">406 patients with NSCLC; 428 unmatched controls</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Any cancer (unspecified degree and tumors among relatives)</td><td align="left" colspan="1" rowspan="1">FHC of 20.4% (cases)</td><td align="left" colspan="1" rowspan="1">85.2% of ever smoker</td><td align="left" colspan="1" rowspan="1">FHC was not associated with diagnosis of NSCLC</td><td align="left" colspan="1" rowspan="1">In patients without FHC, the miR-196a2 CT/TT germline genotype was associated with diagnosis of NSCLC</td></tr><tr><td align="left" colspan="1" rowspan="1">Schwartz et al Carcinogenesis (2011)</td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1">USA/Black (African-Americans)</td><td align="left" colspan="1" rowspan="1">837 cases with lung cancer; 975 matched controls</td><td align="left" colspan="1" rowspan="1">NSCLC, SCLC and others</td><td align="left" colspan="1" rowspan="1">Lung cancer (unspecified degree among relatives)</td><td align="left" colspan="1" rowspan="1">FH of lung cancer of 22%</td><td align="left" colspan="1" rowspan="1">8.2% of never smokers, 91.8% of ever smokers</td><td align="left" colspan="1" rowspan="1">FH of lung cancer was significantly associated with diagnosis of lung cancer (p&#8201;&lt;&#8201;0.001)</td><td align="left" colspan="1" rowspan="1">Excess European ancestry on chromosome 1 at rs6587361 for NSCLC. Excess African ancestry on chromosome 3 at rs181696 among ever smokers with NSCLC</td></tr><tr><td align="left" colspan="1" rowspan="1">Sin et al J Clin Oncol (2013)</td><td align="left" colspan="1" rowspan="1">Retrospective study with exploratory and validation cohorts</td><td align="left" colspan="1" rowspan="1">Canada/White (97.6%), Asian (0.9%), Black (0.6%)</td><td align="left" colspan="1" rowspan="1">2,485 patients from the Pan-Can Study 61 Cases and 122 matched controls from the CARET study</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Lung cancer (unspecified degree among relatives)</td><td align="left" colspan="1" rowspan="1">FH of lung cancer 5.37%</td><td align="left" colspan="1" rowspan="1">All patients reported a history of smoking</td><td align="left" colspan="1" rowspan="1">FH and risk of lung cancer were not associated with diagnosis of NSCLC in the Pan-Can cohort</td><td align="left" colspan="1" rowspan="1"><p>Pro&#8211;Surfactant Protein B (SFTPB&#8212;log transformed) associated with diagnosis of lung cancer</p><p>No association between FH of lung cancer and SFTPB</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Xu et al PLoS One (2013)</td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1">China/Asian</td><td align="left" colspan="1" rowspan="1">1017 male patients with lung cancer; 1017 matched healthy controls 242 cases assessed for clinical outcomes</td><td align="left" colspan="1" rowspan="1">NSCLC, SCLC and others</td><td align="left" colspan="1" rowspan="1">Any cancer (unspecified degree and tumors among relatives)</td><td align="left" colspan="1" rowspan="1">FHC of 12.8% (cases)</td><td align="left" colspan="1" rowspan="1">14.8% of never smokers, 36.4% of former smokers 48.8% of current smokers</td><td align="left" colspan="1" rowspan="1">FHC was significantly associated with the diagnosis of lung cancer</td><td align="left" colspan="1" rowspan="1">Germline rs1564483GA, AA and GA&#8201;+&#8201;AA BCL2 SNPs were associated with decreased risk of lung cancer among patients with not FHC</td></tr><tr><td align="left" colspan="1" rowspan="1">He et al J Hum Genet (2013)</td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1">China/Asian</td><td align="left" colspan="1" rowspan="1">507 patients with NSCLC; 662 unmatched controls</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Lung cancer (unspecified degree among relatives)</td><td align="left" colspan="1" rowspan="1">FH of lung cancer of 21.7% (cases)</td><td align="left" colspan="1" rowspan="1">36.9% of never smokers, 43.1% of ever smokers</td><td align="left" colspan="1" rowspan="1"><p>FH of lung cancer was associated with the diagnosis of NSCLC (OR 1.47, 95%CI: 1.09&#8211;1.98)</p><p>FH of lung cancer was associated with the diagnosis of NSCLC even among smokers (OR 1.94, 95%CI: 1.21&#8211;3.12)</p></td><td align="left" colspan="1" rowspan="1"><p>Several XRCC3 and XRCC4 germ-line SNPs were associated with the diagnosis of NSCLC</p><p>Some XRCC3 and XRCC4 haplotypes and diplotypes were associated with diagnosis of NSCLC, with synergistic effect for increased risk with FH of lung cancer</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Yilmaz et al Asian Pac J Cancer Prev (2014)</td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1">Turkey/not available</td><td align="left" colspan="1" rowspan="1">100 patients with lung cancer; 100 matched healthy controls</td><td align="left" colspan="1" rowspan="1">NSCLC, SCLC and others</td><td align="left" colspan="1" rowspan="1">Any cancer (unspecified degree and tumors among relatives)</td><td align="left" colspan="1" rowspan="1">FHC of 23%</td><td align="left" colspan="1" rowspan="1">90% of smokers</td><td align="left" colspan="1" rowspan="1">FHC was significantly associated with diagnosis of lung cancer diagnosis (p&#8201;=&#8201;0.001)</td><td align="left" colspan="1" rowspan="1">No association between MTHFR C677T polymorphism and diagnosis of lung cancer</td></tr><tr><td align="left" colspan="1" rowspan="1">Pathak et al J Cancer Ther Res (2014)</td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1">USA/White (83%), Black (17%)</td><td align="left" colspan="1" rowspan="1">453 female patients with NSCLC; 478 matched controls</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Lung cancer (unspecified degree and tumors among relatives)</td><td align="left" colspan="1" rowspan="1">FH of lung cancer of 24% among white participants and 28.7% among Black participants</td><td align="left" colspan="1" rowspan="1">90.3% and 91.5% of ever smokers among White and African American, respectively</td><td align="left" colspan="1" rowspan="1">FH of lung cancer was associated with diagnosis of lung cancer in both whites and Black participants (p&#8201;&lt;&#8201;0.01)</td><td align="left" colspan="1" rowspan="1">Germline single nucleotide polymorphisms (SNP) APAF-1 rs1007573 and CD40 rs1535045 were associated with lung cancer in white participants, while SNP TP63 rs6790167 was associated with lung cancer in black participants</td></tr><tr><td align="left" colspan="1" rowspan="1">Tian et al Cell Biochem Biophys (2014)</td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1">China/Asian</td><td align="left" colspan="1" rowspan="1">391 patients with NSCLC; 663 matched controls</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Any cancer (unspecified degree and tumors among relatives)</td><td align="left" colspan="1" rowspan="1">FHC of 27.4% (cases)</td><td align="left" colspan="1" rowspan="1">25.8% of ever smokers</td><td align="left" colspan="1" rowspan="1">FHC was associated with the diagnosis of NSCLC</td><td align="left" colspan="1" rowspan="1">Significant enrichment of germline NQO1 C609T TT SNP compared to CC among cases Germline NQO1 C609T TT SNP was associated with diagnosis of NSCLC after adjustment for FHC</td></tr><tr><td align="left" colspan="1" rowspan="1">Li et al Int J Clin Exp Med (2016)</td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1">China/Asian</td><td align="left" colspan="1" rowspan="1">420 patients with lung cancer aged&#8201;&#8804;&#8201;45&#160;years; 1673 matched controls</td><td align="left" colspan="1" rowspan="1">NSCLC, SCLC and others (cases)</td><td align="left" colspan="1" rowspan="1">Lung cancer (first-, second-degree relatives and collateral relatives)</td><td align="left" colspan="1" rowspan="1">FH of lung cancer of 7.3%</td><td align="left" colspan="1" rowspan="1">27.6% of never smokers, 72.4% of ever smokers</td><td align="left" colspan="1" rowspan="1">FH of lung cancer was associated with diagnosis of lung cancer risk (p&#8201;=&#8201;0.03)</td><td align="left" colspan="1" rowspan="1">FH of lung cancer among first- and second-degree relatives more strongly associated with diagnosis of lung cancer than FH of lung cancer among collateral relatives</td></tr><tr><td align="left" colspan="1" rowspan="1">White and Horvitz (2017)</td><td align="left" colspan="1" rowspan="1">Case&#8211;control study, exploratory</td><td align="left" colspan="1" rowspan="1">USA/not available</td><td align="left" colspan="1" rowspan="1">5443 web-identified potential cases and remaining 4,813,985 web users as controls</td><td align="left" colspan="1" rowspan="1">Likely diagnosis of lung cancer</td><td align="left" colspan="1" rowspan="1">Lung cancer (unspecified degree among relatives)</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">FHC associated with likely diagnosis of lung cancer (RR 7.548, 95% CI 3.9&#8211;14.4)</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Tammemagi et al Lancet Oncol (2017)</td><td align="left" colspan="1" rowspan="1">Prospective, single arm study</td><td align="left" colspan="1" rowspan="1">Canada/White (97%), Black (3%)</td><td align="left" colspan="1" rowspan="1">164 patients with lung cancer among 2537 ever-smoker enrolled subjects between 50 and 75&#160;years without history of cancer at enrollment</td><td align="left" colspan="1" rowspan="1">NSCLC, SCLC and others</td><td align="left" colspan="1" rowspan="1">Lung cancer (first-degree relatives)</td><td align="left" colspan="1" rowspan="1">FH of lung cancer 39%</td><td align="left" colspan="1" rowspan="1">All patients reported a history of smoking</td><td align="left" colspan="1" rowspan="1">No significant association between FH of lung cancer and diagnosis of lung cancer within the study population</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Warkentin et al JNCI Cancer Spectr (2018)</td><td align="left" colspan="1" rowspan="1">Observational, retrospective. Case-case study</td><td align="left" colspan="1" rowspan="1">USA/White (96.9%)</td><td align="left" colspan="1" rowspan="1">64 patients with SA-NSCLC and 206 non-SA-NSCLC cases enrolled in the National Cancer Institute&#8217;s National Lung Screening Trial</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Lung cancer (first-degree relatives)</td><td align="left" colspan="1" rowspan="1">FH of lung cancer 31.8%</td><td align="left" colspan="1" rowspan="1">All patients reported a history of smoking</td><td align="left" colspan="1" rowspan="1">FH of lung cancer was not associated with diagnosis of SA-NSCLC</td><td align="left" colspan="1" rowspan="1">FH of lung cancer associated with SA-NSCLC among female patients</td></tr><tr><td align="left" colspan="1" rowspan="1">Brown et al Cancer Epidemiol Biomarkers Prev (2019)</td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1">USA/White (93.5%), Black (5.3%)</td><td align="left" colspan="1" rowspan="1">262 cases with lung cancer; 528 matched controls</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Lung cancer (unspecified degree among relatives)</td><td align="left" colspan="1" rowspan="1">FH of lung cancer 22.9%</td><td align="left" colspan="1" rowspan="1">All patients reported a history of smoking</td><td align="left" colspan="1" rowspan="1">No significant association between FH of lung cancer and diagnosis of lung cancer within the study population</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Titan et al J Thorac Cardiovasc Surg (2020)</td><td align="left" colspan="1" rowspan="1">Observational, retrospective</td><td align="left" colspan="1" rowspan="1">USA/ White (88.6%)</td><td align="left" colspan="1" rowspan="1">75,587 female patients aged from 50 to 74&#160;years enrolled in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO)</td><td align="left" colspan="1" rowspan="1">1147 patients with NSCLC</td><td align="left" colspan="1" rowspan="1">Any cancer and Lung cancer (unspecified degree and tumors among relatives)</td><td align="left" colspan="1" rowspan="1">FHC of 59.4% and FH of lung cancer of 11.4% (whole study cohort)</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">FH of lung cancer was associated with the risk of developing NSCLC over time (HR 1.79, 95%CI: 1.56&#8211;2.06)</td><td align="left" colspan="1" rowspan="1">FH of lung cancer is associated with the risk of developing NSCLC independently of hormone replacement therapy</td></tr><tr><td align="left" colspan="1" rowspan="1">Jin et al Int J Cancer (2021)</td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1">Japan, China, USA, Singapore, Malaysia and others/Asian</td><td align="left" colspan="1" rowspan="1">Pooled analysis of the International Lung Cancer Consortium (ILCCO) including 264 women with lung cancer and 5342 matched controls</td><td align="left" colspan="1" rowspan="1">NSCLC, SCLC and others</td><td align="left" colspan="1" rowspan="1">Lung cancer (first-degree relatives)</td><td align="left" colspan="1" rowspan="1">FH of lung cancer 6.2%</td><td align="left" colspan="1" rowspan="1">65.3% of never smokers, 10.5% of former smokers, 23.7% of current smokers</td><td align="left" colspan="1" rowspan="1">FH of lung cancer was significantly associated with diagnosis of lung cancer (p&#8201;&lt;&#8201;0.01)</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Lancheros et al Nutrients (2022)</td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1">Spain/Caucasian</td><td align="left" colspan="1" rowspan="1">204 cases of NSCLC; 408 unmatched controls</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Any cancer (unspecified degree and tumors among relatives)</td><td align="left" colspan="1" rowspan="1">FHC of 49.5% (cases)</td><td align="left" colspan="1" rowspan="1">13.24% of never smokers, 39.71% of former smokers, 47.96% of current smokers</td><td align="left" colspan="1" rowspan="1">FHC was associated with diagnosis of NSCLC (OR 15.2, 95%CI: 9.55&#8211;25.2)</td><td align="left" colspan="1" rowspan="1">The Vitamin D Receptor (VDR) BsmI rs1544410-AA germline SNP was associated with lower risk of NSCLC after adjusting for FHC and smoking</td></tr><tr><td align="left" colspan="1" rowspan="1">Albano et al Cancer Epidemiol (2023)</td><td align="left" colspan="1" rowspan="1">Observational, retrospective</td><td align="left" colspan="1" rowspan="1">USA/not available</td><td align="left" colspan="1" rowspan="1">16,056 never smoker patients with 579 cases of lung cancer</td><td align="left" colspan="1" rowspan="1">Lung cancer (not specified)</td><td align="left" colspan="1" rowspan="1">Lung cancer (unspecified degree among relatives)</td><td align="left" colspan="1" rowspan="1">FH of lung cancer 28.7%</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">FH of lung cancer was associated with diagnosis of lung cancer (OR 1.87, 95% CI 1.55&#8211;2&#8211;26)</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Rifkin et al. Clin Lung Cancer (2023)</td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1">United Kingdom/Withes (94.7%)</td><td align="left" colspan="1" rowspan="1">2050 patients with lung cancer/198533 controls</td><td align="left" colspan="1" rowspan="1">Lung cancer (not specified)</td><td align="left" colspan="1" rowspan="1">Lung cancer (unspecified degree among relatives)</td><td align="left" colspan="1" rowspan="1">FH of lung cancer of 21.0%</td><td align="left" colspan="1" rowspan="1">20% of never smokers, 46.6% of former smokers, 33.4% of current smokers</td><td align="left" colspan="1" rowspan="1">FH of lung cancer was significantly associated with diagnosis of lung cancer</td><td align="left" colspan="1" rowspan="1">FH of lung cancer (whole cohort including cases and controls) was significantly associated to germline mutations in 3 significant genes (ATM, BRCA2, TP53)</td></tr><tr><td align="left" colspan="1" rowspan="1">Liu et al Nutrients (2023)</td><td align="left" colspan="1" rowspan="1">Observational, retrospective</td><td align="left" colspan="1" rowspan="1">China/Asian</td><td align="left" colspan="1" rowspan="1">1283 patients with NSCLC and 215 patients with benign lung nodules</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Any cancer (unspecified degree and tumors among relatives)</td><td align="left" colspan="1" rowspan="1">FHC 20.7%</td><td align="left" colspan="1" rowspan="1">62.9% of never smokers, 14.2% of former-smokers, 22.9% of current smokers</td><td align="left" colspan="1" rowspan="1">FHC was not associated with diagnosis of NSCLC</td><td align="left" colspan="1" rowspan="1">FHC was associated with diagnosis of intrapulmonary metastasis among patients with NSCLC at univariable analysis</td></tr></tbody></table><table-wrap-foot><p>NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer; OR: odds ratio; RR: relative risk; HR: hazard ratio; 95%CI 95% confidence intervals; SNPs: single nucleotide polymorphisms</p></table-wrap-foot></table-wrap></p><p id="Par19">One study reported a more pronounced increased risk for women aged&#8201;&#8804;&#8201;45&#160;years and a synergistic effect of smoking and FHC in increasing the risk of lung cancer [<xref ref-type="bibr" rid="CR29">29</xref>], while another study reported that FH of lung cancer was specifically associated with an increased risk of early on set lung cancer (&lt;&#8201;55&#160;years old) [<xref ref-type="bibr" rid="CR17">17</xref>]. One study that failed to demonstrate an association between FHC and lung cancer diagnosis, reported a significant effect for patients in whom at least one relative with cancer was diagnosed&#8201;&lt;&#8201;50&#160;years of age [<xref ref-type="bibr" rid="CR20">20</xref>], while one study that failed to demonstrate an association between FH of lung cancer and lung cancer risk, reported a significant effect for female patients only [<xref ref-type="bibr" rid="CR42">42</xref>].</p><p id="Par20">One study confirmed that FH of lung cancer was associated with risk of lung cancer in both the whole study population and among smokers [<xref ref-type="bibr" rid="CR37">37</xref>], while another study reported that FH of lung cancer was more strongly associated with lung cancer risk in case of first/second degree of relatedness compared to collateral relatives [<xref ref-type="bibr" rid="CR40">40</xref>].</p></sec><sec id="Sec7"><title>Studies investigating the potential impact of FHC on clinical outcomes.</title><p id="Par21">Five studies reported on the potential role of FHC in determining clinical outcomes (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>) [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR48">48</xref>&#8211;<xref ref-type="bibr" rid="CR52">52</xref>]. One study reported no association between FH of lung cancer and outcomes [<xref ref-type="bibr" rid="CR48">48</xref>], two studies reported a differential effect for FHC and FH of lung cancer [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR49">49</xref>] and one study reported a decreased risk of death for patients with FHC [<xref ref-type="bibr" rid="CR50">50</xref>]. Similarly, one study reported improving outcomes from PD-1 immunotherapy with increasing burden of FHC [<xref ref-type="bibr" rid="CR52">52</xref>].<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>summary of the included studies reporting on the potential implication of FHC on clinical outcomes</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Study</th><th align="left" colspan="1" rowspan="1">Design</th><th align="left" colspan="1" rowspan="1">Country/Race</th><th align="left" colspan="1" rowspan="1">Study Population</th><th align="left" colspan="1" rowspan="1">Histology</th><th align="left" colspan="1" rowspan="1">Type of FHC</th><th align="left" colspan="1" rowspan="1">Prevalence of FHC among cases</th><th align="left" colspan="1" rowspan="1">Smoking status details (cases)</th><th align="left" colspan="1" rowspan="1">Main findings</th><th align="left" colspan="1" rowspan="1">Additional findings</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Yang et al Ann Clin Lab Sci (2008)</td><td align="left" colspan="1" rowspan="1">Observational, retrospective</td><td align="left" colspan="1" rowspan="1">USA/not available</td><td align="left" colspan="1" rowspan="1">133 patients with resected stage I-IIIA NSCLC</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Lung cancer (first-degree relatives)</td><td align="left" colspan="1" rowspan="1">FH of lung cancer of 43%</td><td align="left" colspan="1" rowspan="1">8% of never smokers, 58% of former smokers, 35% of current smokers</td><td align="left" colspan="1" rowspan="1">FH of lung cancer was not associated with relative risk of death</td><td align="left" colspan="1" rowspan="1">FH of lung cancer was not associated with hHpr1/p84/Thoc1 expression on tumor samples</td></tr><tr><td align="left" colspan="1" rowspan="1">Li et al Fam Cancer (2011)</td><td align="left" colspan="1" rowspan="1">Observational, restrospective</td><td align="left" colspan="1" rowspan="1">China/Asian</td><td align="left" colspan="1" rowspan="1">539 patients with FHC, including 233 patients with FH of lung cancer among a cohort of 4491 patients with NSCLC</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Any cancer (first-degree and second-degree relatives)</td><td align="left" colspan="1" rowspan="1">FHC of 12%, FH of lung cancer of 5.2%</td><td align="left" colspan="1" rowspan="1"><p>Among patients with no FHC 66.2% pf ever smokers</p><p>Among patients with FHC 60.1% of ever smokers</p></td><td align="left" colspan="1" rowspan="1"><p>FHC was significantly associated with decreased response to chemotherapy (p&#8201;=&#8201;0.024)</p><p>FH of lung cancer was associated with improved survival among early-stage NSCLC (p&#8201;=&#8201;0.015)</p></td><td align="left" colspan="1" rowspan="1"><p>FHC was significantly associated with adenocarcinoma histology, advanced stage disease, non-smoking status, younger age at diagnosis and female gender</p><p>FH of lung cancer was significantly associated with younger age at diagnosis, adenocarcinoma histology, advanced stage disease</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Li et al Life Science Journal (2013)</td><td align="left" colspan="1" rowspan="1">Observational, prospective</td><td align="left" colspan="1" rowspan="1">China/Asian</td><td align="left" colspan="1" rowspan="1">60 patients undergoing resection for NSCLC</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Any cancer (unspecified degree and tumors among relatives)</td><td align="left" colspan="1" rowspan="1">FHC of 20%</td><td align="left" colspan="1" rowspan="1">61.7% of ever smokers</td><td align="left" colspan="1" rowspan="1">FHC was significantly associated with reduced relative risk of death (RR 0.52, 95%CI: 0.16&#8211;0.92)</td><td align="left" colspan="1" rowspan="1">The expression of ERCC1 mRNA was significantly associated with shorter survival</td></tr><tr><td align="left" colspan="1" rowspan="1">Su et al Cell Physiol Biochem (2015)</td><td align="left" colspan="1" rowspan="1">Observational, retrospective</td><td align="left" colspan="1" rowspan="1">China/Asian</td><td align="left" colspan="1" rowspan="1">610 patients with NSCLC</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Any cancer (unspecified degree and tumors among relatives)</td><td align="left" colspan="1" rowspan="1">FHC of 17.5%</td><td align="left" colspan="1" rowspan="1">29.0% of never smokers, 23.28% of former smokers, 47.7% of current smokers</td><td align="left" colspan="1" rowspan="1">FHC was not associated with survival</td><td align="left" colspan="1" rowspan="1"><p>Germline <italic toggle="yes">hOGG1</italic> (rs1052133 C&#8201;&gt;&#8201;G) SNP was associated with shorter survival among patients without FHC</p><p>The hOGG1 G allele correlated with shorter survival among patients without FHC (HR 1.60, 95%CI: 1.04 &#8211; 2.45)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Isla et al Anticancer Res (2016)</td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1">Spain/not available</td><td align="left" colspan="1" rowspan="1">876 female patients with FHC and 886 female patients without FHC</td><td align="left" colspan="1" rowspan="1">NSCLC and SCLC</td><td align="left" colspan="1" rowspan="1">Any cancer (first-degree and second-degree relatives)</td><td align="left" colspan="1" rowspan="1">FHC of 42.5% among the whole cohort; 43.5% among patients with SCLC; 42.4% among patients with NSCLC</td><td align="left" colspan="1" rowspan="1"><p>Among patients without FHC: 43% of never smokers, 15.7% of former smokers, 40.5% of current smokers</p><p>Among patients with FHC: 36.4% of never smokers, 15.6% former smokers, 47.2 current smokers</p></td><td align="left" colspan="1" rowspan="1"><p>FHC was not associated with tumor type (NSCLC vs SCLC)</p><p>Positive smoking personal history was significantly associated with FHC (p&#8201;=&#8201;0.036)</p></td><td align="left" colspan="1" rowspan="1">Positive FHC was associated with shorter OS (23 vs 25.3&#160;months, p&#8201;=&#8201;0.029)</td></tr><tr><td align="left" colspan="1" rowspan="1">Lee et al Lung Cancer (2019)</td><td align="left" colspan="1" rowspan="1">Observational, retrospective</td><td align="left" colspan="1" rowspan="1">Korea/Asian</td><td align="left" colspan="1" rowspan="1">604 female patients who never smoked with resected lung adenocarcinoma</td><td align="left" colspan="1" rowspan="1">Adenocarcinoma</td><td align="left" colspan="1" rowspan="1">Any cancer, categorized as pulmonary and non-pulmonary cancer (first degree relatives)</td><td align="left" colspan="1" rowspan="1">FHC of 29.1%, FH of lung cancer 7.3%</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"><p>FH of non-pulmonary cancer was significantly associated with higher risk of recurrence (HR 1.9, 95%CI: 1.40&#8211;2.56) and death (HR 1.67, 95%CI: 1.18&#8211;2.37), compared with those with no FHC</p><p>FH of pulmonary cancer was not associated with recurrence and/or death</p></td><td align="left" colspan="1" rowspan="1"><p>FH of non-pulmonary cancer was associated with younger age at diagnosis</p><p>FH of pulmonary cancer was associated with an increased rate of EGFR mutation</p><p>FH of non-pulmonary cancer was associated with ALK/ROS-1/RET fusion status</p><p>No association between FH and KRAS status</p><p>Non-significant increase of CDH1 germline mutations in patients with non-pulmonary FH</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Cortellini et al J Hematol Oncol (2022)</td><td align="left" colspan="1" rowspan="1">Case control study</td><td align="left" colspan="1" rowspan="1">Italy/not specified</td><td align="left" colspan="1" rowspan="1">723 patients with NSCLC treated with pembrolizumab (cases); 652 patients with NSCLC treated with chemotherapy (controls)</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Any cancer in lineal line (descendants or ascendants) and collateral line (non-descendants/ascendants, relatives)</td><td align="left" colspan="1" rowspan="1">FHC of 37.5% (cases) 49.3% (controls)</td><td align="left" colspan="1" rowspan="1"><p>Pembrolizumab cohort: 12.4% of never smokers and 87.6% of ever smokers</p><p>Chemotherapy cohort: 12.6% of never smokers and 87.4% of ever smokers</p></td><td align="left" colspan="1" rowspan="1">High burden of FHC associated with improved outcomes compared to low burden/negative FHC among patients treated with pembrolizumab only</td><td align="left" colspan="1" rowspan="1">FHC was not associated with tumor mutational burden, PD-L1 status and somatic DNA damage and response genes status</td></tr></tbody></table><table-wrap-foot><p>NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer; RR: relative risk; HR: hazard ratio; 95%CI 95% confidence intervals</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec8"><title>Studies investigating associations between FHC and germline mutations.</title><p id="Par22">Overall, 12 studies reported on the potential relationship between FHC and germline mutations (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>) [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR53">53</xref>&#8211;<xref ref-type="bibr" rid="CR57">57</xref>]. Two studies did not show an enrichment of the germline mutations/polymorphisms of interest in patients with FHC [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR55">55</xref>], while three studies suggested a potential enrichment [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR57">57</xref>], with only one of them specifically reporting an increased rate of germline mutations including <italic toggle="yes">ATM, BRCA2</italic> and<italic toggle="yes"> TP53</italic> for patients with family history of lung cancer compared to those with no FH [<xref ref-type="bibr" rid="CR46">46</xref>]. Two studies reported a significant effect of the germline status in increasing the risk of lung cancer among patients with no FHC [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR36">36</xref>], while in three other studies the effect was independent of FHC [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. One study showed a synergistic effect in increasing the risk of lung cancer of <italic toggle="yes">XRCC3/XRCC4</italic> variants and FHC [<xref ref-type="bibr" rid="CR37">37</xref>]. Two studies investigated the potential impact of germline polymorphisms on clinical outcomes, one showing an association between <italic toggle="yes">hOGG1</italic> single nucleotide polymorphisms and worse survival specifically in patients without FHC [<xref ref-type="bibr" rid="CR51">51</xref>], the other showing multifaceted effects of germline NOTCH4 polymorphisms depending on the FHC status [<xref ref-type="bibr" rid="CR56">56</xref>].<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table&#160;3</label><caption><p>summary of the included studies reporting on the potential association between FHC and germline mutations</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Study</th><th align="left" colspan="1" rowspan="1">Design</th><th align="left" colspan="1" rowspan="1">Country/Race</th><th align="left" colspan="1" rowspan="1">Study Population</th><th align="left" colspan="1" rowspan="1">Histology</th><th align="left" colspan="1" rowspan="1">Type of FHC</th><th align="left" colspan="1" rowspan="1">Prevalence of FHC among cases</th><th align="left" colspan="1" rowspan="1">Smoking status details (cases)</th><th align="left" colspan="1" rowspan="1">Main findings</th><th align="left" colspan="1" rowspan="1">Additional findings</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Tefre et al Br J Cancer (1990)</td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1">Norway/not available</td><td align="left" colspan="1" rowspan="1">83 patients with lung cancer; 129 unmatched healthy controls</td><td align="left" colspan="1" rowspan="1">SCLC and NSCLC</td><td align="left" colspan="1" rowspan="1">Any cancer (unspecified degree and tumors among relatives)</td><td align="left" colspan="1" rowspan="1">Not available</td><td align="left" colspan="1" rowspan="1">4.8% of never smokers</td><td align="left" colspan="1" rowspan="1">FH of cancer was not associated with germline EcoR1 polymorphism of L-myc</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Hong et al J Prev Med Public Health (2011)</td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1">Korea/Asian</td><td align="left" colspan="1" rowspan="1">406 patients with NSCLC; 428 unmatched controls</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Any cancer (unspecified degree and tumors among relatives)</td><td align="left" colspan="1" rowspan="1">FHC of 20.4% (cases)</td><td align="left" colspan="1" rowspan="1">85.2% of ever smoker</td><td align="left" colspan="1" rowspan="1">FHC was not associated with diagnosis of NSCLC</td><td align="left" colspan="1" rowspan="1">In patients without FHC, the miR-196a2 CT/TT germline genotype was associated with diagnosis of NSCLC</td></tr><tr><td align="left" colspan="1" rowspan="1">Xu et al PLoS One (2013)</td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1">China/Asian</td><td align="left" colspan="1" rowspan="1">1017 male patients with lung cancer; 1017 matched healthy controls</td><td align="left" colspan="1" rowspan="1">NSCLC, SCLC and others</td><td align="left" colspan="1" rowspan="1">Any cancer (unspecified degree and tumors among relatives)</td><td align="left" colspan="1" rowspan="1">FHC of 12.8% (cases)</td><td align="left" colspan="1" rowspan="1">14.8% of never smokers, 36.4% of former smokers 48.8% of current smokers</td><td align="left" colspan="1" rowspan="1">FHC was significantly associated with the diagnosis of lung cancer</td><td align="left" colspan="1" rowspan="1">Germline rs1564483GA, AA and GA&#8201;+&#8201;AA BCL2 SNPs were associated with decreased risk of lung cancer among patients with not FHC</td></tr><tr><td align="left" colspan="1" rowspan="1">He et al J Hum Genet (2013)</td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1">China/Asian</td><td align="left" colspan="1" rowspan="1">507 patients with NSCLC; 662 unmatched controls</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Lung cancer (unspecified degree among relatives)</td><td align="left" colspan="1" rowspan="1">FH of lung cancer of 21.7% (cases)</td><td align="left" colspan="1" rowspan="1">36.9% of never smokers, 43.1% of ever smokers</td><td align="left" colspan="1" rowspan="1"><p>FH of lung cancer was associated with the diagnosis of NSCLC (OR 1.47, 95%CI: 1.09&#8211;1.98)</p><p>FH of lung cancer was associated with the diagnosis of NSCLC even among smokers (OR 1.94, 95%CI: 1.21&#8211;3.12)</p></td><td align="left" colspan="1" rowspan="1"><p>Several XRCC3 and XRCC4 germ-line SNPs were associated with the diagnosis of NSCLC</p><p>Some XRCC3 and XRCC4 haplotypes and diplotypes were associated with diagnosis of NSCLC, with synergistic effect for increased risk with FH of lung cancer</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Tian et al Cell Biochem Biophys (2014)</td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1">China/Asian</td><td align="left" colspan="1" rowspan="1">391 patients with NSCLC; 663 matched controls</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Any cancer (unspecified degree and tumors among relatives)</td><td align="left" colspan="1" rowspan="1">FHC of 27.4% (cases)</td><td align="left" colspan="1" rowspan="1">25.8% of ever smokers</td><td align="left" colspan="1" rowspan="1">FHC was associated with the diagnosis of NSCLC</td><td align="left" colspan="1" rowspan="1"><p>Significant enrichment of germline NQO1 C609T TT SNP compared to CC among cases</p><p>Germline NQO1 C609T TT SNP was associated with diagnosis of NSCLC after adjustment for FHC</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Su et al Cell Physiol Biochem (2015)</td><td align="left" colspan="1" rowspan="1">Observational, retrospective</td><td align="left" colspan="1" rowspan="1">China/Asian</td><td align="left" colspan="1" rowspan="1">610 patients with NSCLC</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Any cancer (unspecified degree and tumors among relatives)</td><td align="left" colspan="1" rowspan="1">FHC of 17.5%</td><td align="left" colspan="1" rowspan="1">29.0% of never smokers, 23.28% of former smokers, 47.7% of current smokers</td><td align="left" colspan="1" rowspan="1">FHC was not associated with survival</td><td align="left" colspan="1" rowspan="1"><p>Germline <italic toggle="yes">hOGG1</italic> (rs1052133 C&#8201;&gt;&#8201;G) SNP was associated with shorter survival among patients without FHC</p><p>The hOGG1 G allele correlated with shorter survival among patients without FHC (HR 1.60, 95%CI: 1.04&#8212;2.45)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Javid et al Clin Transl Oncol (2015)</td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1">India/not available</td><td align="left" colspan="1" rowspan="1">155 patients with NSCLC; 155 matched controls</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Any cancer (unspecified degree and tumors among relatives)</td><td align="left" colspan="1" rowspan="1">FHC of 12.2% (cases)</td><td align="left" colspan="1" rowspan="1">28.4% of never smokers, 71.6% of ever smokers</td><td align="left" colspan="1" rowspan="1"><p>Polymorphism in the inhibitory P2</p><p>promoter region of anti-apoptotic BCL-2 genes was associated with diagnosis of NSCLC (-938CC/AC)</p></td><td align="left" colspan="1" rowspan="1">Patients with FHC enriched in BCL92 (-938AA) genotype</td></tr><tr><td align="left" colspan="1" rowspan="1">Liu et al J Thorac Oncol (2016)</td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1">USA/White</td><td align="left" colspan="1" rowspan="1">54 patients with familial lung cancer and 48 patients with sporadic lung cancer</td><td align="left" colspan="1" rowspan="1">NSCLC, SCLC and others</td><td align="left" colspan="1" rowspan="1">Lung cancer (in at least 3 first-degree relatives)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">14.8% of never smokers, 85.2% of ever smokers</td><td align="left" colspan="1" rowspan="1">Patients with FH of lung cancer were younger, with higher prevalence of female and never smokers than those with sporadic lung cancer,</td><td align="left" colspan="1" rowspan="1"><p>30 germline variants of interest found in 33.3% of patients with FH and 29.2% of patients with no FH</p><p>Patients with FH of lung cancer were not significantly enriched of deleterious mutations found in the whole study population [heterozygous c.2086C&#8201;&gt;&#8201;T in the coiled-coil domain-containing 147 gene (CCD147), and two SNV p.Val26Met and p.Met563Thr, of the dopamine beta-hydroxylase gene (DBH)]</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Xu et al Cancer Manag Res (2019)</td><td align="left" colspan="1" rowspan="1">Observational, retrospective</td><td align="left" colspan="1" rowspan="1">China/Asian</td><td align="left" colspan="1" rowspan="1">987 patients with NSCLC</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Any cancer (unspecified degree and tumors among relatives)</td><td align="left" colspan="1" rowspan="1">FHC of 20.2%</td><td align="left" colspan="1" rowspan="1">62.4% of never smokers, 37.6% of ever smokers</td><td align="left" colspan="1" rowspan="1">No association between FHC and survival</td><td align="left" colspan="1" rowspan="1"><p>Germline rs915894 AC/CC genotype of the <italic toggle="yes">NOTCH4</italic> gene was associated with decreased risk of death, with a greater effect among patients with FHC</p><p>Patients with rs915894 AA genotype of the <italic toggle="yes">NOTCH4</italic> gene and positive FHC showed increased risk of death</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Liu et al Transl Lung Cancer Res (2020)</td><td align="left" colspan="1" rowspan="1">Retrospective study</td><td align="left" colspan="1" rowspan="1">China/Asian</td><td align="left" colspan="1" rowspan="1">1026 patients with NSCLC</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Lung cancer (in at least one first-degree relatives)</td><td align="left" colspan="1" rowspan="1">FH of lung cancer of 26.8%</td><td align="left" colspan="1" rowspan="1">43.1% of never smokers, 56.9% of ever smokers</td><td align="left" colspan="1" rowspan="1">Germline mutations categorized as pathogenic, likely pathogenic or non-pathogenic group</td><td align="left" colspan="1" rowspan="1">Patients with FH of lung cancer were significantly enriched in pathogenetic (57.1%) and likely pathogenetic (32.3%) mutations, compared to non-pathogenetic (26.2%) (p&#8201;=&#8201;0.026)</td></tr><tr><td align="left" colspan="1" rowspan="1">Lancheros et al Nutrients (2022)</td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1">Spain/Caucasian</td><td align="left" colspan="1" rowspan="1">204 cases of NSCLC; 408 unmatched controls</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Any cancer (unspecified degree and tumors among relatives)</td><td align="left" colspan="1" rowspan="1">FHC of 49.5% (cases)</td><td align="left" colspan="1" rowspan="1">13.24% of never smokers, 39.71% of former smokers, 47.96% of current smokers</td><td align="left" colspan="1" rowspan="1">FHC was associated with diagnosis of NSCLC (OR 15.2, 95%CI: 9.55&#8211;25.2)</td><td align="left" colspan="1" rowspan="1">The Vitamin D Receptor (VDR) BsmI rs1544410-AA germline SNP was associated with lower risk of NSCLC after adjusting for FHC and smoking</td></tr><tr><td align="left" colspan="1" rowspan="1">Rifkin et al. Clin Lung Cancer (2023)</td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1">United Kingdom/Withes (94.7%)</td><td align="left" colspan="1" rowspan="1">2050 patients with lung cancer/198533 controls</td><td align="left" colspan="1" rowspan="1">Lung cancer (not specified)</td><td align="left" colspan="1" rowspan="1">Lung cancer (unspecified degree among relatives)</td><td align="left" colspan="1" rowspan="1">FH of lung cancer of 21.0%</td><td align="left" colspan="1" rowspan="1">20% of never smokers, 46.6% of former smokers, 33.4% of current smokers</td><td align="left" colspan="1" rowspan="1">FH of lung cancer was significantly associated with diagnosis of lung cancer</td><td align="left" colspan="1" rowspan="1">FH of lung cancer (whole cohort including cases and controls) was significantly associated to germline mutations in 3 significant genes (ATM, BRCA2, TP53)</td></tr></tbody></table><table-wrap-foot><p>NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer; OR: odds ratio; 95%CI 95% confidence intervals; SNPs: single nucleotide polymorphisms</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec9"><title>Studies investigating associations between FHC and lung cancer somatic features.</title><p id="Par23">Seven studies reported on the potential association between FHC and lung cancer somatic features (Table&#160;<xref rid="Tab4" ref-type="table">4</xref>) [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR58">58</xref>&#8211;<xref ref-type="bibr" rid="CR62">62</xref>]. Three studies did not confirm significant associations between FHC and somatic microsatellite instability status [<xref ref-type="bibr" rid="CR58">58</xref>], somatic DDR genes status [<xref ref-type="bibr" rid="CR52">52</xref>], or <italic toggle="yes">KRAS</italic> mutational status [<xref ref-type="bibr" rid="CR59">59</xref>], while 2 studies reported a significant association between FHC and<italic toggle="yes"> EGFR</italic> mutation [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. In addition, another study reported an association between FHC and the occurrence of multiple somatic mutations in patients tested for multiple genes [<xref ref-type="bibr" rid="CR62">62</xref>].<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table&#160;4</label><caption><p>summary of the included studies reporting on the potential association between FHC and somatic features</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Study</th><th align="left" colspan="1" rowspan="1">Design</th><th align="left" colspan="1" rowspan="1">Country/race</th><th align="left" colspan="1" rowspan="1">Study population</th><th align="left" colspan="1" rowspan="1">Histology</th><th align="left" colspan="1" rowspan="1">Type of FHC</th><th align="left" colspan="1" rowspan="1">Prevalence of FHC among cases</th><th align="left" colspan="1" rowspan="1">Smoking status details (cases)</th><th align="left" colspan="1" rowspan="1">Main findings</th><th align="left" colspan="1" rowspan="1">Additional findings</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><p>Suzuki et al</p><p>Br J Cancer</p><p>(1998)</p></td><td align="left" colspan="1" rowspan="1">Observational, retrospective</td><td align="left" colspan="1" rowspan="1">Japan/Asian</td><td align="left" colspan="1" rowspan="1">136 female patients with NSCLC with FHC and 243 female patients with NSCLC and no FHC</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Any cancer (first-degree relatives)</td><td align="left" colspan="1" rowspan="1">FHC of 35.9% among the study population</td><td align="left" colspan="1" rowspan="1">69.4% of never smokers</td><td align="left" colspan="1" rowspan="1">Microsatellite instability (MSI) was associated to high burden of FHC (at least 3 relatives diagnosed with cancer) compared to controls</td><td align="left" colspan="1" rowspan="1">No significant difference in clinicopathological characteristics between patients with MSI and those without MSI</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Yilmaz et al</p><p>Int J Environ Res Public Health (2014)</p></td><td align="left" colspan="1" rowspan="1">Observational, retrospective</td><td align="left" colspan="1" rowspan="1">USA/not available</td><td align="left" colspan="1" rowspan="1">108 patients with NSCLC and 116 with colorectal cancer</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Any cancer (unspecified degree and tumors among relatives)</td><td align="left" colspan="1" rowspan="1">FHC of 63.2% among patients with NSCLC</td><td align="left" colspan="1" rowspan="1">Among KRAS positive 91.7% of ever smokers Among KRAS negative 69.2% of ever smokers</td><td align="left" colspan="1" rowspan="1">FHC was not associated with KRAS mutational status</td><td align="left" colspan="1" rowspan="1">Among KRAS positive, positive FHC was more frequently reported among patients with NSCLC than those with colorectal cancer</td></tr><tr><td align="left" colspan="1" rowspan="1">Cheng and Cheng J Thorac Dis (2015)</td><td align="left" colspan="1" rowspan="1">Case&#8211;control study (retrospective)</td><td align="left" colspan="1" rowspan="1">Taiwan/Asian</td><td align="left" colspan="1" rowspan="1">85 never smoker (&lt;&#8201;100 cigarette in lifetime) patients with NSCLC and positive FHC; 161 patients with NSCLC with no FHC (serving as controls)</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1"><p>Any cancer (first-degree and second-degree relatives)</p><p>Categorization into pulmonary and non-pulmonary tumors</p></td><td align="left" colspan="1" rowspan="1">FHC of 34.5% among the whole study population</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">FHC was associated with EGFR mutation status (OR 5.9, 95%CI: 3.3&#8211;10.6)</td><td align="left" colspan="1" rowspan="1"><p>FH of pulmonary cancer was associated with EGFR mutation status (OR 7.5, 95%CI: 3.4&#8211;16.3)</p><p>FH of non-pulmonary cancer was associated with EGFR mutation status (OR 5.0, 95%CI: 2.5&#8211;10.0)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Hsu et al Oncotarget (2016)</td><td align="left" colspan="1" rowspan="1">Observational, retrospective</td><td align="left" colspan="1" rowspan="1">Taiwan/Asian</td><td align="left" colspan="1" rowspan="1"><p>131 patients with EGFR positive NSCLC and FH of lung cancer; 1582 patients with EGFR positive NSCLC and no FHC (serving as controls)</p><p>Additional sub-cohort of patients with EGFR positive NSCLC with at least 2 relatives with lung cancer</p></td><td align="left" colspan="1" rowspan="1">Adenocarcinoma (EGFR positive patients)</td><td align="left" colspan="1" rowspan="1">Lung cancer (first-degree relatives)</td><td align="left" colspan="1" rowspan="1">FH of lung cancer of 7.6% among the whole population</td><td align="left" colspan="1" rowspan="1">80.9% of never smokers, 19.1% of ever smokers</td><td align="left" colspan="1" rowspan="1">FH of lung cancer was associated with EGFR mutational status in multivariable models (OR 1.68, 95%CI: 1.06&#8211;2.67)</td><td align="left" colspan="1" rowspan="1"><p>FH of lung cancer was associated with younger age at diagnosis, with lower TNM stage correlated with younger age at diagnosis</p><p>No additional findings from cohort 2</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Cortellini et al J Hematol Oncol (2022)</td><td align="left" colspan="1" rowspan="1">Case control study</td><td align="left" colspan="1" rowspan="1">Italy/not specified</td><td align="left" colspan="1" rowspan="1">723 patients with NSCLC treated with pembrolizumab (cases); 652 patients with NSCLC treated with chemotherapy (controls)</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Any cancer in lineal line (descendants or ascendants) and collateral line (non-descendants/ascendants, relatives)</td><td align="left" colspan="1" rowspan="1">FHC of 37.5% (cases) 49.3% (controls)</td><td align="left" colspan="1" rowspan="1"><p>Pembrolizumab cohort: 12.4% of never smokers and 87.6% of ever smokers</p><p>Chemotherapy cohort: 12.6% of never smokers and 87.4% of ever smokers</p></td><td align="left" colspan="1" rowspan="1">High burden of FHC associated with improved outcomes compared to low burden/negative FHC among patients treated with pembrolizumab only</td><td align="left" colspan="1" rowspan="1">FHC was not associated with tumor mutational burden, PD-L1 status and somatic DNA damage and response genes status</td></tr><tr><td align="left" colspan="1" rowspan="1">Chang et al Future Oncol (2022)</td><td align="left" colspan="1" rowspan="1">Observational, retrospective</td><td align="left" colspan="1" rowspan="1">China/Asian</td><td align="left" colspan="1" rowspan="1">517 patients with NSCLC categorized into wild-type, single-gene mutation (50.87%) and concomitant mutations (11.99%)</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Any cancer (unspecified degree and tumors among relatives)</td><td align="left" colspan="1" rowspan="1">FHC of 6.18% among the whole cohort</td><td align="left" colspan="1" rowspan="1">61.3% of never smokers, 15.8% of former smokers, 23.40% of current smokers</td><td align="left" colspan="1" rowspan="1">FHC was significantly associated with the presence of concomitant mutations, compared to single gene/wild-type group</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Lashkrizedeh et al Clin Respir J (2023)</td><td align="left" colspan="1" rowspan="1">Cross-sectional study</td><td align="left" colspan="1" rowspan="1">Iran/not available</td><td align="left" colspan="1" rowspan="1">100 patients with lung cancer</td><td align="left" colspan="1" rowspan="1">NSCLC and SCLC</td><td align="left" colspan="1" rowspan="1">FH of lung cancer (unspecified degree among relatives)</td><td align="left" colspan="1" rowspan="1">FH of lung cancer of 5%</td><td align="left" colspan="1" rowspan="1">16% of never smokers, 84% of ever smokers</td><td align="left" colspan="1" rowspan="1">No association between FH of lung cancer and HER2/neu status</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr></tbody></table><table-wrap-foot><p>NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer; OR: odds ratio; 95%CI 95% confidence intervals</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec10"><title>Studies investigating associations between FHC and other lung cancer features.</title><p id="Par24">Nine studies included in this subgroup reported on associations between FHC and other lung cancer features (Table&#160;<xref rid="Tab5" ref-type="table">5</xref>) [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR63">63</xref>&#8211;<xref ref-type="bibr" rid="CR67">67</xref>]. One study reported a link between younger age at diagnosis female gender and FHC [<xref ref-type="bibr" rid="CR63">63</xref>], one study reported an increased prevalence of FH of breast cancer among female patients with lung cancer [<xref ref-type="bibr" rid="CR64">64</xref>], while another study reported a 10-years increasing trend over time for the prevalence of FHC [<xref ref-type="bibr" rid="CR22">22</xref>]. Importantly, one study reported a significant association between FHC and smoking [<xref ref-type="bibr" rid="CR19">19</xref>], while another study reported that FH of lung cancer was more frequent among young women, with synergistic effect with smoking and coil exposure in determining the younger age at diagnosis [<xref ref-type="bibr" rid="CR21">21</xref>].<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table&#160;5</label><caption><p>summary of the included studies reporting on the potential association between FHC and other features</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Study</th><th align="left" colspan="1" rowspan="1">Design</th><th align="left" colspan="1" rowspan="1">Country/Race</th><th align="left" colspan="1" rowspan="1">Study Population</th><th align="left" colspan="1" rowspan="1">Histology</th><th align="left" colspan="1" rowspan="1">Type of FHC</th><th align="left" colspan="1" rowspan="1">Prevalence of FHC among cases</th><th align="left" colspan="1" rowspan="1">Smoking status details (cases)</th><th align="left" colspan="1" rowspan="1">Main findings</th><th align="left" colspan="1" rowspan="1">Additional findings</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Ambrosone et al Cancer (1993)</td><td align="left" colspan="1" rowspan="1">Observational, retrospective</td><td align="left" colspan="1" rowspan="1">USA/not available</td><td align="left" colspan="1" rowspan="1">339 female; 533 male patients with lung cancer</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Any cancer (first-degree relatives)</td><td align="left" colspan="1" rowspan="1">FHC of 44.3% among the study population</td><td align="left" colspan="1" rowspan="1">9% of never smokers, 91% of ever smokers</td><td align="left" colspan="1" rowspan="1"><p>Age at diagnosis&#8201;&lt;&#8201;57&#160;years was significantly associated with FHC among patients with squamous cell carcinoma patients (p&#8201;&lt;&#8201;0.01)</p><p>Female diagnosed at&#8201;&lt;&#8201;57&#160;years reported higher prevalence of positive FHC (75%) compared to male (57%) (p&#8201;&lt;&#8201;0.05)</p></td><td align="left" colspan="1" rowspan="1">Reduced prevalence of positive FHC among non-smokers with adenocarcinoma histology than among non-smoker with squamous cell carcinoma histology and SCLC</td></tr><tr><td align="left" colspan="1" rowspan="1">Tsuchiya et al Jpn J Clin Oncol (2007)</td><td align="left" colspan="1" rowspan="1">Observational, cross sectional</td><td align="left" colspan="1" rowspan="1">Japan/Asian</td><td align="left" colspan="1" rowspan="1">1566 patients with lung cancer</td><td align="left" colspan="1" rowspan="1">NSCLC and SCLC</td><td align="left" colspan="1" rowspan="1">Gastric, colon, lung, breast cancer (first-degree relatives)</td><td align="left" colspan="1" rowspan="1">FH of lung cancer 12% and 14% among male and female cases. FH of other cancers of 29.7% and 33.3% among male and female cases</td><td align="left" colspan="1" rowspan="1">Among males: 5% of never smokers, 95% of ever smokers. Among females: 68.3% of never smoker, 31.7% of ever smokers</td><td align="left" colspan="1" rowspan="1">Increased prevalence of FH of breast cancer among female cases compared to male cases</td><td align="left" colspan="1" rowspan="1">No statistical difference in first-degree FH of stomach, colon, and lung cancer between male and female cases</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Isla et al</p><p>Anticancer Res (2016)</p></td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1">Spain/not available</td><td align="left" colspan="1" rowspan="1">876 female patients with FHC and 886 female patients without FHC</td><td align="left" colspan="1" rowspan="1">NSCLC and SCLC</td><td align="left" colspan="1" rowspan="1">Any cancer (first-degree and second-degree relatives)</td><td align="left" colspan="1" rowspan="1">FHC of 42.5% among the whole cohort; 43.5% among patients with SCLC; 42.4% among patients with NSCLC</td><td align="left" colspan="1" rowspan="1"><p>Among patients without FHC: 43% of never smokers, 15.7% of former smokers, 40.5% of current smokers</p><p>Among patients with FHC: 36.4% of never smokers, 15.6% former smokers, 47.2 current smokers</p></td><td align="left" colspan="1" rowspan="1"><p>FHC was not associated with tumor type (NSCLC vs SCLC)</p><p>Positive smoking personal history was significantly associated with FHC (p&#8201;=&#8201;0.036)</p></td><td align="left" colspan="1" rowspan="1">Positive FHC was associated with shorter OS (23 vs 25.3&#160;months, p&#8201;=&#8201;0.029)</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Banik et al</p><p>Health Qual Life Outcomes</p><p>(2017)</p></td><td align="left" colspan="1" rowspan="1">Observational, prospective</td><td align="left" colspan="1" rowspan="1">Poland/not available</td><td align="left" colspan="1" rowspan="1">102 patients undergoing resection for NSCLC</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Any cancer (first-degree relatives)</td><td align="left" colspan="1" rowspan="1">FHC of 54%</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><p>FHC was not associated with patients&#8217; awareness</p><p>FHC was significantly associated with lower physical quality of life. FHC was associated with decreased self-efficacy and emotional quality of life</p></td><td align="left" colspan="1" rowspan="1"><p>FHC was not associated with with stage at diagnosis/gender</p><p>Increasing symptoms reported among women with FHC</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Chen et al</p><p>Thorac Cancer (2019)</p></td><td align="left" colspan="1" rowspan="1">Observational, retrospective</td><td align="left" colspan="1" rowspan="1">China/Asian</td><td align="left" colspan="1" rowspan="1">410 patients with NSCLC screened for tobacco and coal exposure</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">FH of lung cancer (defined as 3 cases of lung cancer among first-degree relatives)</td><td align="left" colspan="1" rowspan="1">FH of lung cancer of 46.8%</td><td align="left" colspan="1" rowspan="1">43.7% of never smokers, 56.3% of ever smokers</td><td align="left" colspan="1" rowspan="1"><p>FH of lung cancer was more frequent in women and younger age at diagnosis</p><p>Synergist association between FH of lung cancer, increasing smoking and coal exposure and younger age at diagnosis</p></td><td align="left" colspan="1" rowspan="1"><p>FH of lung cancer more frequent among patients with NSCLC, patients with stage IV tumors and among patients with ALK positive NSCLC</p><p>Synergist association between FH of lung cancer, increasing smoking and coal exposure and ALK positive status, with no association between FH of lung cancer and ALK status among those with low exposure</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Gaur et al</p><p>J Cancer Res Ther (2020)</p></td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1">India</td><td align="left" colspan="1" rowspan="1">201 patients with lung cancer; 100 unmatched healthy controls</td><td align="left" colspan="1" rowspan="1">NSCLC, SCLC, and others</td><td align="left" colspan="1" rowspan="1">Any cancer (unspecified degree and tumors among relatives)</td><td align="left" colspan="1" rowspan="1">FHC of 5.4%</td><td align="left" colspan="1" rowspan="1">23.4% of never smokers, 31.8% of former smokers, 41.3% of current smokers</td><td align="left" colspan="1" rowspan="1">FHC of 5.4%</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Zang et al Ann Thorac Surg</p><p>(2020)</p></td><td align="left" colspan="1" rowspan="1">Observational, retrospective</td><td align="left" colspan="1" rowspan="1">China/Asian</td><td align="left" colspan="1" rowspan="1">7184 patients with primary lung cancer</td><td align="left" colspan="1" rowspan="1">NSCLC, SCLC and others</td><td align="left" colspan="1" rowspan="1">Any cancer and lung cancer (unspecified degree among relatives)</td><td align="left" colspan="1" rowspan="1">FH of any cancer 8.3%, FH of lung cancer 3.2%</td><td align="left" colspan="1" rowspan="1">Prevalence of ever smokers in the whole cohort was 57.6%</td><td align="left" colspan="1" rowspan="1">10-years increase in FHC (from 7% to 11.5%, p&#8201;&lt;&#8201;0.001)</td><td align="left" colspan="1" rowspan="1">FH of lung cancer did not increase over the 10-years study window</td></tr><tr><td align="left" colspan="1" rowspan="1">Chen et al Front Surg (2022)</td><td align="left" colspan="1" rowspan="1">Case&#8211;control study</td><td align="left" colspan="1" rowspan="1">Taiwan/Asian</td><td align="left" colspan="1" rowspan="1">79 non intubated (cases) and 158 intubated (controls) patients after video-assisted thoracoscopic surgery (VATS) resection for lung cancer and aged at least 75&#160;years</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">Any cancer (unspecified degree and tumors among relatives)</td><td align="left" colspan="1" rowspan="1">FHC of 11.4% (whole study population)</td><td align="left" colspan="1" rowspan="1">24.1% of never smokers</td><td align="left" colspan="1" rowspan="1">FHC was not associated to intubation</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Li et al Front Oncol (2022)</td><td align="left" colspan="1" rowspan="1">Observational, retrospective</td><td align="left" colspan="1" rowspan="1">China/Asian</td><td align="left" colspan="1" rowspan="1">31 patients with pulmonary mucoepidermoid carcinoma</td><td align="left" colspan="1" rowspan="1">Mucoepidermoid carcinoma</td><td align="left" colspan="1" rowspan="1">Any cancer (unspecified degree among relatives)</td><td align="left" colspan="1" rowspan="1">FH of any cancer 19.9%</td><td align="left" colspan="1" rowspan="1">51.6% of ever smokers</td><td align="left" colspan="1" rowspan="1">FH of any cancer 19.9%</td><td align="left" colspan="1" rowspan="1">No association between FHC and tumor grade</td></tr></tbody></table><table-wrap-foot><p>NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec11"><title>FAHIC lung&#8212;methods/design</title><sec id="Sec12"><title>Study design and objectives</title><p id="Par25">The FAHIC&#8212;Lung study (observational, prospective, multicenter study to investigate the family history of cancer in patients with non-small cell lung cancer) is a cross-sectional/prospective, observational, multicenter study. Consecutive patients with histologically diagnosed NSCLC will be enrolled, regardless of their age, TNM stage, smoking status, and other clinicopathologic characteristics. ClinicalTrials.gov identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06196424">NCT06196424</ext-link>.</p><p id="Par26">The primary objective of the study is the identification of FHC patterns and within-family clusters of other risk factors to address patients with NSCLC for systematic genetic counseling for germline next-generation sequencing (NGS) testing to identify PGVs and likely PGVs. Secondary objectives include the description of clinicopathological and oncological characteristics of patients with NSCLC according to FHC patterns.</p><p id="Par27">Patients&#8217; family history will be carefully collected by investigators through a dedicated self-reported study questionnaire, which has been developed for the purpose of this study and validated by the genetic expert of the steering committee (F.G.) (Supplementary file 2). Study questionnaire will focus on: (1) family history of cancer; (2) type of tumors/primary tumor sites among relatives with history of cancer; (3) age at diagnosis among relatives with history of cancer; (4) biological sex of relatives with history of cancer; (5) exposure to tobacco smoking and smoking habits among relatives with history of cancer; (6) geographical origin of participants and relatives with history of cancer; (7) personal history of multiple malignancies; (8) potential professional and environmental exposure to carcinogens of participants and relatives with history of cancer; (9) ethnicity of both participants and relatives with history of cancer.</p><p id="Par28">To minimize risks of recalling bias, patients will be followed up for four weeks through two study visits: the first study visit at enrolment and the follow-up study visit. During the first study visit all patient&#8217;s clinic-pathologic will be collected and study participants will be given the ad-hoc questionnaire, which will be returned to the study personnel at the follow-up study visit (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>FAHIC-lung study design diagram</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="12967_2024_5538_Fig2_HTML.jpg"/></fig></p><p id="Par29">The following clinic-pathologic characteristics will be collected: (1) smoking status (active/passive, package/year, total years of smoking); (2) Eastern Cooperative Oncology Group Performance Status (ECOG-PS); (3) age at diagnosis; (4) tumor histology; (5) tumor stage at diagnosis according to the 8th edition of TNM staging system; (6) ethnicity; (7) professional and environmental exposure to carcinogens; (8) programmed death ligand-1 tumor proportion score (PD&#8212;L1 TPS); (9) any available oncogenic drivers including <italic toggle="yes">EGFR, KRAS, BRAF, c-MET</italic>, mutations and <italic toggle="yes">ALK, ROS-1, RET, NTRK</italic> translocation/gene fusions; (10) personal history of other synchronous/metachronous primary malignancies.</p><p id="Par30">The study plan includes an observational phase and an analytical phase:</p><p id="Par31"><italic toggle="yes">Observational phase</italic>: after collecting participants&#8217; questionnaires, we will first reconstruct patients&#8217; family trees with additional information on how other potential risk factors, such as smoking history and exposure to professional/environmental carcinogens, segregate within the families with a history of cancer.</p><p id="Par32"><italic toggle="yes">Analytical phase</italic>: once we have identified family clusters of malignancies and risk factors potentially associated with the highest risk of being carriers of germline PGVs or likely PGVs, we will proceed with the collection of blood samples for germline testing in a subgroup of patients. This will enable us to assess and compare the prevalence of PGVs/likely PGVs between patients more likely to be carriers and the control cohort. This approach aims to achieve a robust comparison, minimize systematic referrals to genetic counseling for all NSCLC patients, and optimize NGS testing requests outside the research setting. Considering the validity and comprehensiveness of high-throughput techniques in identifying PGVs/likely PGVs [<xref ref-type="bibr" rid="CR68">68</xref>], we will assess the germline status of the groups of interest through whole exome sequencing (WES) after DNA extraction from blood samples in a two step analysis.</p><p id="Par33">In the first step, the raw sequencing data (FASTQ files) will undergo bioinformatic processing. Mapping will be performed using a high-throughput aligner to ensure accurate alignment of the sequenced reads to the human genome. Variant calling will then be conducted to identify deviations from the reference genome. Filtering and annotation of these variants will focus on a pre-specified list of pre-specified genes known to be associated potentially associated with cancer (Supplementary file 3). This curated gene list will be used to prioritize PGVs/likely PGVs variants. Online tools will be utilized for variant prioritization, organizing the genes based on their correlation with lung cancer, thus enabling us to pinpoint the most relevant variants for further investigation.</p><p id="Par34">In the second step, we aim to discover novel variants that may contribute to lung cancer predisposition. This phase involves a more exploratory analysis of the FASTQ data, looking beyond the known pathogenic variants. We will leverage the extensive genealogical data we have collected on the patients&#8217; family histories to identify potential new genetic markers. The stored FASTQ files will be re-analyzed to detect previously unreported variants, incorporating bioinformatics tools and techniques for variant discovery. These include advanced algorithms for variant detection and annotation, as well as integrative approaches to assess the potential pathogenicity of novel variants. The integration of genealogical data will enhance our ability to correlate these novel variants with familial patterns of lung cancer, potentially uncovering new genetic predispositions. This comprehensive approach ensures that we maximize the utility of the sequencing data, providing a robust platform for both targeted and discovery-driven genetic analysis.</p></sec><sec id="Sec13"><title>Participants selection</title><p id="Par35">Inclusion Criteria include: (1) histopathological diagnosis of NSCLC (all stages); (2) age&#8201;&#8805;&#8201;18&#160;years old; (3) signed written informed consent; (4) availability of familiar and/or personal anamnestic data of cancer. Exclusion Criteria include: (1) unavailability of familiar and/or personal anamnestic data of cancer; (2) patient&#8217;s refusal.</p></sec><sec id="Sec14"><title>Statistical plan and sample size</title><p id="Par36">The sample size of patients enrolled has been determined only for the observational phase of the study. This determination focuses on identifying patients who are more likely to be carriers of pathogenic germline variants (PGVs) or likely PGVs. This approach acknowledges the lack of information on the prevalence of germline PGVs/likely PGVs in patients with NSCLC who are not selected based on family history of cancer (FHC), as well as the limited knowledge regarding the potential characteristics that will define our group of interest. We hypothesized a prevalence of 10% of participants with an especially enriched family history of cancer to be directed to systematic germline testing; assuming a confidence level of 95% with a total width for the confidence interval of 0.1 (precision of&#8201;&#177;&#8201;5%), the minimum number of subjects needed to properly describe the group of interest, following a binomial &#8220;exact&#8221; calculation of the sample size, is 175. To account for potential dropouts, we will enroll a minimum of 180 patients.</p><p id="Par37">Descriptive statistics will be used as appropriate to report FHC data, the distribution of within-family other risk factors, and baseline clinicopathologic characteristics. Analyses will be performed using R-Studio software (R Core Team, 2021), and MedCalc&#174; Statistical Software version 20 (MedCalc Software Ltd, Ostend, Belgium; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.medcalc.org">https://www.medcalc.org</ext-link>; 2021).</p></sec></sec><sec id="Sec15"><title>Discussion</title><p id="Par38">To the best of our knowledge, this is the first systematic review summarizing the available evidence on the role of FHC in patients with lung cancer, and the FAHIC-lung study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06196424">NCT06196424</ext-link>) is the first cross-sectional/prospective study specifically designed to identify patients with NSCLC more likely to be carrier of PGVs/likely PGVs, that should be systematically referred to genetic counselling and germline testing.</p><p id="Par39">Our review shows that few studies have focused on the family history of cancer (FHC) in patients with lung cancer, resulting in overall heterogeneous results, beginning with the extremely wide range of FHC and family history of lung cancer rates. The category with the highest number of reports included studies assessing FHC as a potential risk factor for developing lung cancer. However, even in this category, the results were largely discordant, with a variety of different approaches and categorizations. Most of the included studies followed a retrospective approach, which is inherently associated with recall bias in collecting family history information, and none used questionnaires specifically designed to collect FHC. To mitigate this bias, we developed our ad-hoc study questionnaire, while the cross-sectional/prospective approach with the 4-week interval will allow study participants to gather and report FHC information as carefully as possible.</p><p id="Par40">Something that set lung cancer apart from other malignancies, where the FHC has an established role in defining the probability of being a carrier of PGVs/likely PGVs, such as ovarian, breast, prostate, and colorectal cancer, is the role of smoking. As mentioned, smoking history represents the main risk factor for lung cancer [<xref ref-type="bibr" rid="CR6">6</xref>], several evidence shows that passive smoking from family members can be a detrimental factor and that even the smoking habit can be &#8220;inherited&#8221;, with a sort of intergenerational transmission [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. The FAHIC-lung questionnaire will allow us to mitigate this potential bias as well, collecting smoking habit information and environmental exposure to carcinogens among patients&#8217; relatives with cancer.</p><p id="Par41">More than a half of the studies that assessed FHC and FH of lung cancer as a potential risk factor for lung cancer concluded that FHC plays a detrimental role, with a potential synergistic effect with smoking, that seems even more pronounced among young/female patients. Our systematic review also suggests that younger patients, female, Asian, and never/light smokers may be especially enriched in FHC, although with no clear/conclusive results, while no somatic genomic feature seems to be significantly associated with FHC, except for <italic toggle="yes">EGFR</italic> mutations.</p><p id="Par42">Recently, increasing attention has been focused on the study of germline mutations as risk factor for lung cancer, highlighting how DDR genes alterations can be found among patients with lung adenocarcinoma, even in the context of wider within-family primary tumors spectrums, including breast/pancreatic cancers or hematological malignancies [<xref ref-type="bibr" rid="CR10">10</xref>]. Even in the context of TP53-associated genetic susceptibility, FHC is gaining a clearer role, to the point of recommending genetic counselling for patients with lung adenocarcinoma younger than 46&#160;years old and with an especially enriched FHC or personal history of multiple primary tumors [<xref ref-type="bibr" rid="CR71">71</xref>].</p><p id="Par43">Importantly, in our systematic review only one of the studies that investigated the multifaceted role of germline mutations reported a significant enrichment among patients with FHC [<xref ref-type="bibr" rid="CR46">46</xref>]. Rifkin and colleagues first reported a systematic review on the evidence linking germline mutations with lung cancer risk, then validated through a large case&#8211;control study of patients undergoing germline whole exome sequencing (WES) the significant association between lung cancer risk and <italic toggle="yes">ATM</italic>,<italic toggle="yes"> BRCA2 </italic>and <italic toggle="yes">TP</italic>53&#160;pathogenetic/likely pathogenetic germline mutations [<xref ref-type="bibr" rid="CR46">46</xref>]. However, despite the overall enrichment among controls, variant-based and gene-based analyses showed a low prevalence of germline PGV/likely PGV in both cases and controls [<xref ref-type="bibr" rid="CR46">46</xref>]. In addition, they reported a higher rate of carriers among study participants with FH of lung cancer compared to those without, but with a very low overall prevalence (0.8% vs 0.7% for the combination of <italic toggle="yes">ATM/BRCA2/TP53</italic>) [<xref ref-type="bibr" rid="CR46">46</xref>], suggesting that a simplified collection of FHC information is not enough to identify patients with the highest probability of being carriers and to properly optimize germ-line NGC access.</p><p id="Par44">Among gene-specific susceptibility for lung cancer, <italic toggle="yes">EGFR</italic>-associated one needs a special mention. Genetic counselling is already recommended for patients with somatic <italic toggle="yes">EGFR</italic> positive NSCLC younger than 50&#160;years, regardless of their family history [<xref ref-type="bibr" rid="CR10">10</xref>], however, a proper syndromic <italic toggle="yes">EGFR</italic>-associated lung cancer should be suspected in the case of the novo <italic toggle="yes">EGFR</italic> T790M mutations, especially with a somatic variant allele frequency (VAF)&#8201;&#8805;&#8201;35% [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR72">72</xref>], with even more rare <italic toggle="yes">EGFR</italic> variants, such as V834L and V843I being increasingly recognized [<xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR74">74</xref>]. Lastly, we will have to consider the complexity related to the multifaceted role of multiple primary tumors. Beyond the consisting evidence linking DDR genes mutations to a personal history of multiple malignancies, recent studies reported on the potential role of pleiotropic loci in determining the risk of multiple malignancies [<xref ref-type="bibr" rid="CR75">75</xref>].</p><p id="Par45">Our study plan has, however, some limitations. First, we will have to rely on patients' ability and willingness to reconstruct their family history, therefore the recall bias will exert a certain effect despite the cross/sectional prospective approach. In addition, we have no strictly predefined definition of potential family clusters to be analyzed. However, we can anticipate that the identified group of interest will likely include young female patients with adenocarcinoma histology, never or light smokers, patients with <italic toggle="yes">EGFR </italic>mutations, patients with a history of multiple primary tumors, and patients with a high burden of family history. This high burden of family history is particularly expected to be enriched in non-smoking associated cancers, including lung cancer, and in the DDR-genes associated cancer spectrum, such as breast, ovarian, prostate, melanoma, and pancreatic cancers.To ensure a comprehensive analysis, we also plan to incorporate other factors collected through our detailed questionnaire. These factors include smoking habits of the patients, passive smoking exposure, working exposure to carcinogens, and smoking habits of family members. By evaluating these additional factors, we aim to identify within-family clusters of other risk factors. Specifically, we will focus on selecting patients without a history of passive smoking, identifying patients with a younger age at diagnosis among their relatives with cancer, and considering patients with low working exposure to carcinogens. Despite having these anticipations, we have deliberately chosen to adopt an unbiased approach without pre-established features to define patients for germline tests. Considering the very low prevalence of germline mutations reported so far [<xref ref-type="bibr" rid="CR46">46</xref>], this strategy allows for a more comprehensive and inclusive analysis, ensuring that we do not overlook any potential associations or risk factors to unravel the complexity of FHC information and identify patients especially enriched in PGVs/likely PGVs. Furthermore, considering that this is an observational study, we decided to adopt a two steps approach, in order to identify patients at risk as a first step. This, to minimize the potential clinical implications for study participants and let their treating physicians refer them to genetic counseling as per their existing clinical practice. Once the group of interest will be identified, we will amend the protocol to collect blood samples and allocate fundings for germline testing. Lastly, we have to consider that the FAIHC lung study is being conducted in Italy, therefore the study population will mostly consist of white/Caucasian patients. Although this will prevent us from gathering broader information on the potential implications of different races, we will be able to focus and obtain reliable results on patients with European ancestry.</p><p id="Par46">In the context of a worldwide progressive implementation of chest computed tomography based screening programs in subject with smoking history [<xref ref-type="bibr" rid="CR76">76</xref>], and considering the initial evidence of the potential benefit of screening programs among never smokers and other subjects potentially enriched in FHC/PGVs [<xref ref-type="bibr" rid="CR77">77</xref>], identifying patients with the highest risk of being carrier of PGVs/likely PGVs would be extremely important to develop dedicated preventing measures in non-smoker subjects. Considering the costs of commercially available germline NGS tests and the potential preventive, prognostic, and therapeutic implications of the detection of germline mutations related to familial cancers, we believe that establishing FHC patterns to identify a subgroup of patients especially enriched in PGVs to direct to germline screening outside of the research setting, would be extremely helpful in optimizing resources, spare time and eventually improve patients&#8217; outcomes.</p></sec><sec sec-type="supplementary-material"><sec id="Sec16"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12967_2024_5538_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary file 1.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12967_2024_5538_MOESM2_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary file 2.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12967_2024_5538_MOESM3_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary file 3.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM4" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12967_2024_5538_MOESM4_ESM.xlsx" position="float" orientation="portrait"><caption><p>Supplementary file 4.</p></caption></media></supplementary-material></p></sec></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>None.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>All authors contributed to the publication according to the ICMJE guidelines for the authorship (study conception and design, acquisition of data, analysis and interpretation of data, drafting of manuscript, critical revision). All authors read and approved the submitted version of the manuscript (and any substantially modified version that involves the author's contribution to the study). Each author has agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.</p></notes><notes notes-type="data-availability"><title>Data Availability</title><p> This systematic review does not involve the generation of new data. The data analyzed in this study are derived from publicly available studies and publications that are cited within the paper. All sources of data, including databases and search strategies used to identify relevant studies, are described in the Methods section. Readers interested in accessing the underlying data can refer to the referenced studies and publications for more detailed information.&#160;Due to data management regulations, individual patient-level data from the FAIHC-lung study are not available. However, inquiries from third parties can be directed to the corresponding author.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par47">All the study procedures will follow the precepts of Good Clinical Practice and the declaration of Helsinki. The study was approved by the local ethical committees on human experimentation (Comitato Etico Territoriale Lazio AREA 2, registro sperimentazioni 27.23 CET 2 CBM, 12 Oct 2023).</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par48">Alessio Cortellini declares speaker&#8217;s fees from MSD, AstraZeneca, Pierre-Fabre, EISAI, Sanofi/REGENERON, and Roche (outside of the present work) and advisory board roles/grant for consultancies from MSD, BMS, AstraZeneca, Roche, OncoC4, IQVIA, Pierre-Fabre, EISAI, REGENERON, Sanofi/REGENERON, Ardelis Health, AlphaSight, Access Infinity (outside of the present work). He also declares travel support from MSD and Roche. Sara Ramella declares advisory board roles and grant consultancies from Astra Zeneca, MSD (Merk) and Roche (outside of the present work). All other authors declare no conflicts of interest associated with the present study.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Guidelines Detail: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.nccn.org/guidelines/guidelines-detail">https://www.nccn.org/guidelines/guidelines-detail</ext-link>.</mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stjepanovic</surname><given-names>N</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>L</given-names></name><name name-style="western"><surname>Carneiro</surname><given-names>F</given-names></name><etal/></person-group><article-title>Hereditary gastrointestinal cancers: ESMO clinical practice guidelines for diagnosis, treatment and follow-up&#8224;</article-title><source>Ann Oncol</source><year>2019</year><volume>30</volume><fpage>1558</fpage><lpage>1571</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdz233</pub-id><pub-id pub-id-type="pmid">31378807</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Stjepanovic N, Moreira L, Carneiro F, et al. Hereditary gastrointestinal cancers: ESMO clinical practice guidelines for diagnosis, treatment and follow-up&#8224;. Ann Oncol. 2019;30:1558&#8211;71.<pub-id pub-id-type="pmid">31378807</pub-id><pub-id pub-id-type="doi">10.1093/annonc/mdz233</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Genetics of Prostate Cancer (PDQ<sup>&#174;</sup>)&#8211;Health Professional Version&#8212;NCI <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cancer.gov/types/prostate/hp/prostate-genetics-pdq">https://www.cancer.gov/types/prostate/hp/prostate-genetics-pdq</ext-link>.<pub-id pub-id-type="pmid">26389227</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Lung Cancer Statistics | How common is lung cancer? <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html">https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html</ext-link>. Accessed 12 Mar 2023.</mixed-citation></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malvezzi</surname><given-names>M</given-names></name><name name-style="western"><surname>Santucci</surname><given-names>C</given-names></name><name name-style="western"><surname>Boffetta</surname><given-names>P</given-names></name><etal/></person-group><article-title>European cancer mortality predictions for the year 2023 with focus on lung cancer</article-title><source>Ann Oncol</source><year>2023</year><volume>34</volume><fpage>410</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2023.01.010</pub-id><pub-id pub-id-type="pmid">36882139</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Malvezzi M, Santucci C, Boffetta P, et al. European cancer mortality predictions for the year 2023 with focus on lung cancer. Ann Oncol. 2023;34:410&#8211;9.<pub-id pub-id-type="pmid">36882139</pub-id><pub-id pub-id-type="doi">10.1016/j.annonc.2023.01.010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steuer</surname><given-names>CE</given-names></name><name name-style="western"><surname>Jegede</surname><given-names>OA</given-names></name><name name-style="western"><surname>Dahlberg</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Smoking behavior in patients with early-stage NSCLC: a report from ECOG-ACRIN 1505 trial</article-title><source>J Thorac Oncol</source><year>2021</year><volume>16</volume><fpage>960</fpage><lpage>967</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2020.12.017</pub-id><pub-id pub-id-type="pmid">33539971</pub-id><pub-id pub-id-type="pmcid">PMC8383783</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Steuer CE, Jegede OA, Dahlberg SE, et al. Smoking behavior in patients with early-stage NSCLC: a report from ECOG-ACRIN 1505 trial. J Thorac Oncol. 2021;16:960&#8211;7.<pub-id pub-id-type="pmid">33539971</pub-id><pub-id pub-id-type="doi">10.1016/j.jtho.2020.12.017</pub-id><pub-id pub-id-type="pmcid">PMC8383783</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malhotra</surname><given-names>J</given-names></name><name name-style="western"><surname>Malvezzi</surname><given-names>M</given-names></name><name name-style="western"><surname>Negri</surname><given-names>E</given-names></name><etal/></person-group><article-title>Risk factors for lung cancer worldwide</article-title><source>Eur Respir J</source><year>2016</year><volume>48</volume><fpage>889</fpage><lpage>902</lpage><pub-id pub-id-type="doi">10.1183/13993003.00359-2016</pub-id><pub-id pub-id-type="pmid">27174888</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Malhotra J, Malvezzi M, Negri E, et al. Risk factors for lung cancer worldwide. Eur Respir J. 2016;48:889&#8211;902.<pub-id pub-id-type="pmid">27174888</pub-id><pub-id pub-id-type="doi">10.1183/13993003.00359-2016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riudavets</surname><given-names>M</given-names></name><name name-style="western"><surname>Garcia de Herreros</surname><given-names>M</given-names></name><name name-style="western"><surname>Besse</surname><given-names>B</given-names></name><etal/></person-group><article-title>Radon and lung cancer: current trends and future perspectives</article-title><source>Cancers</source><year>2022</year><volume>14</volume><fpage>3142</fpage><pub-id pub-id-type="doi">10.3390/cancers14133142</pub-id><pub-id pub-id-type="pmid">35804914</pub-id><pub-id pub-id-type="pmcid">PMC9264880</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Riudavets M, Garcia de Herreros M, Besse B, et al. Radon and lung cancer: current trends and future perspectives. Cancers. 2022;14:3142.<pub-id pub-id-type="pmid">35804914</pub-id><pub-id pub-id-type="doi">10.3390/cancers14133142</pub-id><pub-id pub-id-type="pmcid">PMC9264880</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">A New Pathway from Air Pollution to Lung Cancer in Non-Smokers <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailyreporter.esmo.org/esmo-congress-2022/research-advances-in-the-last-months/a-pathway-from-air-pollution-to-lung-cancer-in-non-smokers-has-been-identified">https://dailyreporter.esmo.org/esmo-congress-2022/research-advances-in-the-last-months/a-pathway-from-air-pollution-to-lung-cancer-in-non-smokers-has-been-identified</ext-link>.</mixed-citation></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benusiglio</surname><given-names>PR</given-names></name><name name-style="western"><surname>Fallet</surname><given-names>V</given-names></name><name name-style="western"><surname>Sanchis-Borja</surname><given-names>M</given-names></name><etal/></person-group><article-title>Lung cancer is also a hereditary disease</article-title><source>Eur Respir Rev</source><year>2021</year><volume>30</volume><fpage>210045</fpage><pub-id pub-id-type="doi">10.1183/16000617.0045-2021</pub-id><pub-id pub-id-type="pmid">34670806</pub-id><pub-id pub-id-type="pmcid">PMC9488670</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Benusiglio PR, Fallet V, Sanchis-Borja M, et al. Lung cancer is also a hereditary disease. Eur Respir Rev. 2021;30: 210045.<pub-id pub-id-type="pmid">34670806</pub-id><pub-id pub-id-type="doi">10.1183/16000617.0045-2021</pub-id><pub-id pub-id-type="pmcid">PMC9488670</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>ET</given-names></name><name name-style="western"><surname>Smedby</surname><given-names>KE</given-names></name><name name-style="western"><surname>Hjalgrim</surname><given-names>H</given-names></name><etal/></person-group><article-title>Reliability of self-reported family history of cancer in a large case-control study of lymphoma</article-title><source>J Natl Cancer Inst</source><year>2006</year><volume>98</volume><fpage>61</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1093/jnci/djj005</pub-id><pub-id pub-id-type="pmid">16391372</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Chang ET, Smedby KE, Hjalgrim H, et al. Reliability of self-reported family history of cancer in a large case-control study of lymphoma. J Natl Cancer Inst. 2006;98:61&#8211;8.<pub-id pub-id-type="pmid">16391372</pub-id><pub-id pub-id-type="doi">10.1093/jnci/djj005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murff</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Spigel</surname><given-names>DR</given-names></name><name name-style="western"><surname>Syngal</surname><given-names>S</given-names></name></person-group><article-title>Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history</article-title><source>JAMA</source><year>2004</year><volume>292</volume><fpage>1480</fpage><lpage>1489</lpage><pub-id pub-id-type="doi">10.1001/jama.292.12.1480</pub-id><pub-id pub-id-type="pmid">15383520</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Murff HJ, Spigel DR, Syngal S. Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA. 2004;292:1480&#8211;9.<pub-id pub-id-type="pmid">15383520</pub-id><pub-id pub-id-type="doi">10.1001/jama.292.12.1480</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sorscher</surname><given-names>S</given-names></name><name name-style="western"><surname>LoPiccolo</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>E</given-names></name><etal/></person-group><article-title>Landscape of pathogenic germline variants in patients with lung cancer</article-title><source>JCO</source><year>2022</year><volume>40</volume><fpage>388570</fpage><lpage>388570</lpage><pub-id pub-id-type="doi">10.1200/JCO.2022.40.36_suppl.388570</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Sorscher S, LoPiccolo J, Chen E, et al. Landscape of pathogenic germline variants in patients with lung cancer. JCO. 2022;40:388570&#8211;388570.<pub-id pub-id-type="doi">10.1200/JCO.2022.40.36_suppl.388570</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnett-Page</surname><given-names>E</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>J</given-names></name></person-group><article-title>Methods for the synthesis of qualitative research: a critical review</article-title><source>BMC Med Res Methodol</source><year>2009</year><volume>9</volume><fpage>59</fpage><pub-id pub-id-type="doi">10.1186/1471-2288-9-59</pub-id><pub-id pub-id-type="pmid">19671152</pub-id><pub-id pub-id-type="pmcid">PMC3224695</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Barnett-Page E, Thomas J. Methods for the synthesis of qualitative research: a critical review. BMC Med Res Methodol. 2009;9:59.<pub-id pub-id-type="pmid">19671152</pub-id><pub-id pub-id-type="doi">10.1186/1471-2288-9-59</pub-id><pub-id pub-id-type="pmcid">PMC3224695</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lashkarizadeh</surname><given-names>M</given-names></name><name name-style="western"><surname>Lashkarizadeh</surname><given-names>M</given-names></name><name name-style="western"><surname>Nikian</surname><given-names>M</given-names></name><etal/></person-group><article-title>The expression of HER2/neu in patients with lung cancer and its associated factors</article-title><source>Clin Respir J</source><year>2023</year><volume>17</volume><fpage>90</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1111/crj.13572</pub-id><pub-id pub-id-type="pmid">36617420</pub-id><pub-id pub-id-type="pmcid">PMC9892694</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Lashkarizadeh M, Lashkarizadeh M, Nikian M, et al. The expression of HER2/neu in patients with lung cancer and its associated factors. Clin Respir J. 2023;17:90&#8211;5.<pub-id pub-id-type="pmid">36617420</pub-id><pub-id pub-id-type="doi">10.1111/crj.13572</pub-id><pub-id pub-id-type="pmcid">PMC9892694</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tammemagi</surname><given-names>MC</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>H</given-names></name><name name-style="western"><surname>Martel</surname><given-names>S</given-names></name><etal/></person-group><article-title>Participant selection for lung cancer screening by risk modelling (the Pan-Canadian early detection of lung cancer [PanCan] study): a single-arm, prospective study</article-title><source>Lancet Oncol</source><year>2017</year><volume>18</volume><fpage>1523</fpage><lpage>1531</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(17)30597-1</pub-id><pub-id pub-id-type="pmid">29055736</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Tammemagi MC, Schmidt H, Martel S, et al. Participant selection for lung cancer screening by risk modelling (the Pan-Canadian early detection of lung cancer [PanCan] study): a single-arm, prospective study. Lancet Oncol. 2017;18:1523&#8211;31.<pub-id pub-id-type="pmid">29055736</pub-id><pub-id pub-id-type="doi">10.1016/S1470-2045(17)30597-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cassidy</surname><given-names>A</given-names></name><name name-style="western"><surname>Balsan</surname><given-names>J</given-names></name><name name-style="western"><surname>Vesin</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cancer diagnosis in first-degree relatives and non-small cell lung cancer risk: results from a multi-centre case-control study in Europe</article-title><source>Eur J Cancer</source><year>2009</year><volume>45</volume><fpage>3047</fpage><lpage>3053</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2009.05.006</pub-id><pub-id pub-id-type="pmid">19482469</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Cassidy A, Balsan J, Vesin A, et al. Cancer diagnosis in first-degree relatives and non-small cell lung cancer risk: results from a multi-centre case-control study in Europe. Eur J Cancer. 2009;45:3047&#8211;53.<pub-id pub-id-type="pmid">19482469</pub-id><pub-id pub-id-type="doi">10.1016/j.ejca.2009.05.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaur</surname><given-names>P</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>S</given-names></name><name name-style="western"><surname>Kant</surname><given-names>S</given-names></name><etal/></person-group><article-title>Hospital-based study on demographic, hematological, and biochemical profile of lung cancer patients</article-title><source>J Cancer Res Ther</source><year>2020</year><volume>16</volume><fpage>839</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.4103/jcrt.JCRT_185_18</pub-id><pub-id pub-id-type="pmid">32930127</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Gaur P, Bhattacharya S, Kant S, et al. Hospital-based study on demographic, hematological, and biochemical profile of lung cancer patients. J Cancer Res Ther. 2020;16:839&#8211;42.<pub-id pub-id-type="pmid">32930127</pub-id><pub-id pub-id-type="doi">10.4103/jcrt.JCRT_185_18</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isla</surname><given-names>D</given-names></name><name name-style="western"><surname>Felip</surname><given-names>E</given-names></name><name name-style="western"><surname>Vi&#241;olas</surname><given-names>N</given-names></name><etal/></person-group><article-title>Lung cancer in women with a family history of cancer: the Spanish female-specific database WORLD07</article-title><source>Anticancer Res</source><year>2016</year><volume>36</volume><fpage>6647</fpage><lpage>6653</lpage><pub-id pub-id-type="doi">10.21873/anticanres.11273</pub-id><pub-id pub-id-type="pmid">27919997</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Isla D, Felip E, Vi&#241;olas N, et al. Lung cancer in women with a family history of cancer: the Spanish female-specific database WORLD07. Anticancer Res. 2016;36:6647&#8211;53.<pub-id pub-id-type="pmid">27919997</pub-id><pub-id pub-id-type="doi">10.21873/anticanres.11273</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gorlova</surname><given-names>OY</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Schabath</surname><given-names>MB</given-names></name><etal/></person-group><article-title>Never smokers and lung cancer risk: a case-control study of epidemiological factors</article-title><source>Int J Cancer</source><year>2006</year><volume>118</volume><fpage>1798</fpage><lpage>1804</lpage><pub-id pub-id-type="doi">10.1002/ijc.21561</pub-id><pub-id pub-id-type="pmid">16217766</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Gorlova OY, Zhang Y, Schabath MB, et al. Never smokers and lung cancer risk: a case-control study of epidemiological factors. Int J Cancer. 2006;118:1798&#8211;804.<pub-id pub-id-type="pmid">16217766</pub-id><pub-id pub-id-type="doi">10.1002/ijc.21561</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>G</given-names></name><name name-style="western"><surname>Lei</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Lung cancer family history and exposure to occupational/domestic coal combustion contribute to variations in clinicopathologic features and gene fusion patterns in non-small cell lung cancer</article-title><source>Thorac Cancer</source><year>2019</year><volume>10</volume><fpage>695</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1111/1759-7714.12987</pub-id><pub-id pub-id-type="pmid">30775858</pub-id><pub-id pub-id-type="pmcid">PMC6449330</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Chen Y, Li G, Lei Y, et al. Lung cancer family history and exposure to occupational/domestic coal combustion contribute to variations in clinicopathologic features and gene fusion patterns in non-small cell lung cancer. Thorac Cancer. 2019;10:695&#8211;707.<pub-id pub-id-type="pmid">30775858</pub-id><pub-id pub-id-type="doi">10.1111/1759-7714.12987</pub-id><pub-id pub-id-type="pmcid">PMC6449330</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zang</surname><given-names>R</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J-F</given-names></name><name name-style="western"><surname>Lerut</surname><given-names>TE</given-names></name><etal/></person-group><article-title>Ten-year trends of clinicopathologic features and surgical treatment of lung cancer in China</article-title><source>Ann Thorac Surg</source><year>2020</year><volume>109</volume><fpage>389</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2019.08.017</pub-id><pub-id pub-id-type="pmid">31526778</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Zang R, Shi J-F, Lerut TE, et al. Ten-year trends of clinicopathologic features and surgical treatment of lung cancer in China. Ann Thorac Surg. 2020;109:389&#8211;95.<pub-id pub-id-type="pmid">31526778</pub-id><pub-id pub-id-type="doi">10.1016/j.athoracsur.2019.08.017</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsugane</surname><given-names>S</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>S</given-names></name><name name-style="western"><surname>Sugimura</surname><given-names>H</given-names></name><etal/></person-group><article-title>Smoking, occupation and family history in lung cancer patients under fifty years of age</article-title><source>Jpn J Clin Oncol</source><year>1987</year><volume>17</volume><fpage>309</fpage><lpage>317</lpage><pub-id pub-id-type="pmid">2826845</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Tsugane S, Watanabe S, Sugimura H, et al. Smoking, occupation and family history in lung cancer patients under fifty years of age. Jpn J Clin Oncol. 1987;17:309&#8211;17.<pub-id pub-id-type="pmid">2826845</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>K-Y</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>C-F</given-names></name><name name-style="western"><surname>Chang</surname><given-names>G-C</given-names></name><etal/></person-group><article-title>Hormone replacement therapy and lung cancer risk in Chinese</article-title><source>Cancer</source><year>2007</year><volume>110</volume><fpage>1768</fpage><lpage>1775</lpage><pub-id pub-id-type="doi">10.1002/cncr.22987</pub-id><pub-id pub-id-type="pmid">17879370</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Chen K-Y, Hsiao C-F, Chang G-C, et al. Hormone replacement therapy and lung cancer risk in Chinese. Cancer. 2007;110:1768&#8211;75.<pub-id pub-id-type="pmid">17879370</pub-id><pub-id pub-id-type="doi">10.1002/cncr.22987</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Titan</surname><given-names>AL</given-names></name><name name-style="western"><surname>He</surname><given-names>H</given-names></name><name name-style="western"><surname>Lui</surname><given-names>N</given-names></name><etal/></person-group><article-title>The influence of hormone replacement therapy on lung cancer incidence and mortality</article-title><source>J Thorac Cardiovasc Surg</source><year>2020</year><volume>159</volume><fpage>1546</fpage><lpage>1556.e4</lpage><pub-id pub-id-type="doi">10.1016/j.jtcvs.2019.10.070</pub-id><pub-id pub-id-type="pmid">31866083</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Titan AL, He H, Lui N, et al. The influence of hormone replacement therapy on lung cancer incidence and mortality. J Thorac Cardiovasc Surg. 2020;159:1546-1556.e4.<pub-id pub-id-type="pmid">31866083</pub-id><pub-id pub-id-type="doi">10.1016/j.jtcvs.2019.10.070</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>K</given-names></name><name name-style="western"><surname>Hung</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S</given-names></name><etal/></person-group><article-title>Hormonal factors in association with lung cancer among Asian women: a pooled analysis from the international lung cancer consortium</article-title><source>Int J Cancer</source><year>2021</year><volume>148</volume><fpage>2241</fpage><lpage>2254</lpage><pub-id pub-id-type="doi">10.1002/ijc.33405</pub-id><pub-id pub-id-type="pmid">33210298</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Jin K, Hung RJ, Thomas S, et al. Hormonal factors in association with lung cancer among Asian women: a pooled analysis from the international lung cancer consortium. Int J Cancer. 2021;148:2241&#8211;54.<pub-id pub-id-type="pmid">33210298</pub-id><pub-id pub-id-type="doi">10.1002/ijc.33405</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pathak</surname><given-names>A</given-names></name><name name-style="western"><surname>Wenzlaff</surname><given-names>AS</given-names></name><name name-style="western"><surname>Hyland</surname><given-names>PL</given-names></name><etal/></person-group><article-title>Apoptosis-related single nucleotide polymorphisms and the risk of non-small cell lung cancer in women</article-title><source>J Cancer Ther Res</source><year>2014</year><volume>3</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.7243/2049-7962-3-1</pub-id><pub-id pub-id-type="pmid">24790730</pub-id><pub-id pub-id-type="pmcid">PMC4002173</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Pathak A, Wenzlaff AS, Hyland PL, et al. Apoptosis-related single nucleotide polymorphisms and the risk of non-small cell lung cancer in women. J Cancer Ther Res. 2014;3:1.<pub-id pub-id-type="pmid">24790730</pub-id><pub-id pub-id-type="doi">10.7243/2049-7962-3-1</pub-id><pub-id pub-id-type="pmcid">PMC4002173</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jeon</surname><given-names>JH</given-names></name><name name-style="western"><surname>Goh</surname><given-names>S-H</given-names></name><etal/></person-group><article-title>The clinical impact of family history of cancer in female never-smoker lung adenocarcinoma</article-title><source>Lung Cancer</source><year>2019</year><volume>136</volume><fpage>15</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2019.07.031</pub-id><pub-id pub-id-type="pmid">31421257</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Lee Y, Jeon JH, Goh S-H, et al. The clinical impact of family history of cancer in female never-smoker lung adenocarcinoma. Lung Cancer. 2019;136:15&#8211;22.<pub-id pub-id-type="pmid">31421257</pub-id><pub-id pub-id-type="doi">10.1016/j.lungcan.2019.07.031</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osann</surname><given-names>KE</given-names></name></person-group><article-title>Lung cancer in women: the importance of smoking, family history of cancer, and medical history of respiratory disease</article-title><source>Cancer Res</source><year>1991</year><volume>51</volume><fpage>4893</fpage><lpage>4897</lpage><pub-id pub-id-type="pmid">1654203</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Osann KE. Lung cancer in women: the importance of smoking, family history of cancer, and medical history of respiratory disease. Cancer Res. 1991;51:4893&#8211;7.<pub-id pub-id-type="pmid">1654203</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwartz</surname><given-names>AG</given-names></name><name name-style="western"><surname>Wenzlaff</surname><given-names>AS</given-names></name><name name-style="western"><surname>Prysak</surname><given-names>GM</given-names></name><etal/></person-group><article-title>Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>5785</fpage><lpage>5792</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.13.3975</pub-id><pub-id pub-id-type="pmid">18089876</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Schwartz AG, Wenzlaff AS, Prysak GM, et al. Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. J Clin Oncol. 2007;25:5785&#8211;92.<pub-id pub-id-type="pmid">18089876</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2007.13.3975</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tammemagi</surname><given-names>CM</given-names></name><name name-style="western"><surname>Freedman</surname><given-names>MT</given-names></name><name name-style="western"><surname>Church</surname><given-names>TR</given-names></name><etal/></person-group><article-title>Factors associated with human small aggressive non small cell lung cancer</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2007</year><volume>16</volume><fpage>2082</fpage><lpage>2089</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-07-0251</pub-id><pub-id pub-id-type="pmid">17932357</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Tammemagi CM, Freedman MT, Church TR, et al. Factors associated with human small aggressive non small cell lung cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:2082&#8211;9.<pub-id pub-id-type="pmid">17932357</pub-id><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-07-0251</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cote</surname><given-names>ML</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>W</given-names></name><name name-style="western"><surname>Wenzlaff</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women</article-title><source>Carcinogenesis</source><year>2009</year><volume>30</volume><fpage>626</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgp033</pub-id><pub-id pub-id-type="pmid">19174490</pub-id><pub-id pub-id-type="pmcid">PMC2664455</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Cote ML, Yoo W, Wenzlaff AS, et al. Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women. Carcinogenesis. 2009;30:626&#8211;35.<pub-id pub-id-type="pmid">19174490</pub-id><pub-id pub-id-type="doi">10.1093/carcin/bgp033</pub-id><pub-id pub-id-type="pmcid">PMC2664455</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>Y-S</given-names></name><name name-style="western"><surname>Kang</surname><given-names>H-J</given-names></name><name name-style="western"><surname>Kwak</surname><given-names>J-Y</given-names></name><etal/></person-group><article-title>Association between microRNA196a2 rs11614913 genotypes and the risk of non-small cell lung cancer in Korean population</article-title><source>J Prev Med Public Health</source><year>2011</year><volume>44</volume><fpage>125</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.3961/jpmph.2011.44.3.125</pub-id><pub-id pub-id-type="pmid">21617338</pub-id><pub-id pub-id-type="pmcid">PMC3249248</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Hong Y-S, Kang H-J, Kwak J-Y, et al. Association between microRNA196a2 rs11614913 genotypes and the risk of non-small cell lung cancer in Korean population. J Prev Med Public Health. 2011;44:125&#8211;30.<pub-id pub-id-type="pmid">21617338</pub-id><pub-id pub-id-type="doi">10.3961/jpmph.2011.44.3.125</pub-id><pub-id pub-id-type="pmcid">PMC3249248</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwartz</surname><given-names>AG</given-names></name><name name-style="western"><surname>Wenzlaff</surname><given-names>AS</given-names></name><name name-style="western"><surname>Bock</surname><given-names>CH</given-names></name><etal/></person-group><article-title>Admixture mapping of lung cancer in 1812 African-Americans</article-title><source>Carcinogenesis</source><year>2011</year><volume>32</volume><fpage>312</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgq252</pub-id><pub-id pub-id-type="pmid">21115650</pub-id><pub-id pub-id-type="pmcid">PMC3047238</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Schwartz AG, Wenzlaff AS, Bock CH, et al. Admixture mapping of lung cancer in 1812 African-Americans. Carcinogenesis. 2011;32:312&#8211;7.<pub-id pub-id-type="pmid">21115650</pub-id><pub-id pub-id-type="doi">10.1093/carcin/bgq252</pub-id><pub-id pub-id-type="pmcid">PMC3047238</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sin</surname><given-names>DD</given-names></name><name name-style="western"><surname>Tammemagi</surname><given-names>CM</given-names></name><name name-style="western"><surname>Lam</surname><given-names>S</given-names></name><etal/></person-group><article-title>Pro-surfactant protein B as a biomarker for lung cancer prediction</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><fpage>4536</fpage><lpage>4543</lpage><pub-id pub-id-type="doi">10.1200/JCO.2013.50.6105</pub-id><pub-id pub-id-type="pmid">24248694</pub-id><pub-id pub-id-type="pmcid">PMC3871515</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Sin DD, Tammemagi CM, Lam S, et al. Pro-surfactant protein B as a biomarker for lung cancer prediction. J Clin Oncol. 2013;31:4536&#8211;43.<pub-id pub-id-type="pmid">24248694</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2013.50.6105</pub-id><pub-id pub-id-type="pmcid">PMC3871515</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>P</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Genetic variation in BCL2 3&#8217;-UTR was associated with lung cancer risk and prognosis in male Chinese population</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><fpage>e72197</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0072197</pub-id><pub-id pub-id-type="pmid">23977251</pub-id><pub-id pub-id-type="pmcid">PMC3745400</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Xu P, Liu L, Wang J, et al. Genetic variation in BCL2 3&#8217;-UTR was associated with lung cancer risk and prognosis in male Chinese population. PLoS ONE. 2013;8: e72197.<pub-id pub-id-type="pmid">23977251</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0072197</pub-id><pub-id pub-id-type="pmcid">PMC3745400</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>F</given-names></name><name name-style="western"><surname>Chang</surname><given-names>S-C</given-names></name><name name-style="western"><surname>Wallar</surname><given-names>GM</given-names></name><etal/></person-group><article-title>Association of XRCC3 and XRCC4 gene polymorphisms, family history of cancer and tobacco smoking with non-small-cell lung cancer in a Chinese population: a case-control study</article-title><source>J Hum Genet</source><year>2013</year><volume>58</volume><fpage>679</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1038/jhg.2013.78</pub-id><pub-id pub-id-type="pmid">23924833</pub-id><pub-id pub-id-type="pmcid">PMC4125205</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">He F, Chang S-C, Wallar GM, et al. Association of XRCC3 and XRCC4 gene polymorphisms, family history of cancer and tobacco smoking with non-small-cell lung cancer in a Chinese population: a case-control study. J Hum Genet. 2013;58:679&#8211;85.<pub-id pub-id-type="pmid">23924833</pub-id><pub-id pub-id-type="doi">10.1038/jhg.2013.78</pub-id><pub-id pub-id-type="pmcid">PMC4125205</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yilmaz</surname><given-names>M</given-names></name><name name-style="western"><surname>Kacan</surname><given-names>T</given-names></name><name name-style="western"><surname>Sari</surname><given-names>I</given-names></name><etal/></person-group><article-title>Lack of association between the MTHFRC677T polymorphism and lung cancer in a Turkish population</article-title><source>Asian Pac J Cancer Prev</source><year>2014</year><volume>15</volume><fpage>6333</fpage><lpage>6337</lpage><pub-id pub-id-type="doi">10.7314/APJCP.2014.15.15.6333</pub-id><pub-id pub-id-type="pmid">25124620</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Yilmaz M, Kacan T, Sari I, et al. Lack of association between the MTHFRC677T polymorphism and lung cancer in a Turkish population. Asian Pac J Cancer Prev. 2014;15:6333&#8211;7.<pub-id pub-id-type="pmid">25124620</pub-id><pub-id pub-id-type="doi">10.7314/APJCP.2014.15.15.6333</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name></person-group><article-title>The role of NQO1 polymorphisms in the susceptibility and chemotherapy response of Chinese NSCLC patients</article-title><source>Cell Biochem Biophys</source><year>2014</year><volume>69</volume><fpage>475</fpage><lpage>479</lpage><pub-id pub-id-type="doi">10.1007/s12013-014-9820-z</pub-id><pub-id pub-id-type="pmid">24464627</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Tian G, Wang M, Xu X. The role of NQO1 polymorphisms in the susceptibility and chemotherapy response of Chinese NSCLC patients. Cell Biochem Biophys. 2014;69:475&#8211;9.<pub-id pub-id-type="pmid">24464627</pub-id><pub-id pub-id-type="doi">10.1007/s12013-014-9820-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F</given-names></name><etal/></person-group><article-title>High risk occupational exposure and family history were risk factors in young lung cancer in Chinese</article-title><source>Int J Clin Exp Med</source><year>2016</year><volume>9</volume><issue>12</issue><fpage>23650</fpage><lpage>23657</lpage></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Li J, Zhang M, Yang F, et al. High risk occupational exposure and family history were risk factors in young lung cancer in Chinese. Int J Clin Exp Med. 2016;9(12):23650&#8211;7.</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>RW</given-names></name><name name-style="western"><surname>Horvitz</surname><given-names>E</given-names></name></person-group><article-title>Evaluation of the feasibility of screening patients for early signs of lung carcinoma in web search logs</article-title><source>JAMA Oncol</source><year>2017</year><volume>3</volume><fpage>398</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2016.4911</pub-id><pub-id pub-id-type="pmid">27832243</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">White RW, Horvitz E. Evaluation of the feasibility of screening patients for early signs of lung carcinoma in web search logs. JAMA Oncol. 2017;3:398&#8211;401.<pub-id pub-id-type="pmid">27832243</pub-id><pub-id pub-id-type="doi">10.1001/jamaoncol.2016.4911</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warkentin</surname><given-names>MT</given-names></name><name name-style="western"><surname>Tammem&#228;gi</surname><given-names>MC</given-names></name><name name-style="western"><surname>Freedman</surname><given-names>MT</given-names></name><etal/></person-group><article-title>Factors associated with small aggressive non-small cell lung cancers in the national lung screening trial: a validation study</article-title><source>JNCI Cancer Spectr</source><year>2018</year><volume>2</volume><fpage>pkx010</fpage><pub-id pub-id-type="doi">10.1093/jncics/pkx010</pub-id><pub-id pub-id-type="pmid">31360836</pub-id><pub-id pub-id-type="pmcid">PMC6649725</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Warkentin MT, Tammem&#228;gi MC, Freedman MT, et al. Factors associated with small aggressive non-small cell lung cancers in the national lung screening trial: a validation study. JNCI Cancer Spectr. 2018;2:pkx010.<pub-id pub-id-type="pmid">31360836</pub-id><pub-id pub-id-type="doi">10.1093/jncics/pkx010</pub-id><pub-id pub-id-type="pmcid">PMC6649725</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>D</given-names></name><name name-style="western"><surname>Zingone</surname><given-names>A</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Relationship between circulating inflammation proteins and lung cancer diagnosis in the national lung screening trial</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2019</year><volume>28</volume><fpage>110</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-18-0598</pub-id><pub-id pub-id-type="pmid">30297515</pub-id><pub-id pub-id-type="pmcid">PMC6325020</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Brown D, Zingone A, Yu Y, et al. Relationship between circulating inflammation proteins and lung cancer diagnosis in the national lung screening trial. Cancer Epidemiol Biomarkers Prev. 2019;28:110&#8211;8.<pub-id pub-id-type="pmid">30297515</pub-id><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-18-0598</pub-id><pub-id pub-id-type="pmcid">PMC6325020</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pineda Lancheros</surname><given-names>LE</given-names></name><name name-style="western"><surname>Rojo Tolosa</surname><given-names>S</given-names></name><name name-style="western"><surname>G&#225;lvez Navas</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Effect of single nucleotide polymorphisms in the vitamin d metabolic pathway on susceptibility to non-small-cell lung cancer</article-title><source>Nutrients</source><year>2022</year><volume>14</volume><fpage>4668</fpage><pub-id pub-id-type="doi">10.3390/nu14214668</pub-id><pub-id pub-id-type="pmid">36364930</pub-id><pub-id pub-id-type="pmcid">PMC9659229</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Pineda Lancheros LE, Rojo Tolosa S, G&#225;lvez Navas JM, et al. Effect of single nucleotide polymorphisms in the vitamin d metabolic pathway on susceptibility to non-small-cell lung cancer. Nutrients. 2022;14:4668.<pub-id pub-id-type="pmid">36364930</pub-id><pub-id pub-id-type="doi">10.3390/nu14214668</pub-id><pub-id pub-id-type="pmcid">PMC9659229</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albano</surname><given-names>D</given-names></name><name name-style="western"><surname>Dhamija</surname><given-names>A</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Lung cancer in nonsmokers&#8212;a risk factor analysis</article-title><source>Cancer Epidemiol</source><year>2023</year><volume>86</volume><fpage>102439</fpage><pub-id pub-id-type="doi">10.1016/j.canep.2023.102439</pub-id><pub-id pub-id-type="pmid">37598649</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Albano D, Dhamija A, Liao Y, et al. Lung cancer in nonsmokers&#8212;a risk factor analysis. Cancer Epidemiol. 2023;86: 102439.<pub-id pub-id-type="pmid">37598649</pub-id><pub-id pub-id-type="doi">10.1016/j.canep.2023.102439</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rifkin</surname><given-names>AS</given-names></name><name name-style="western"><surname>Less</surname><given-names>EM</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J</given-names></name><etal/></person-group><article-title>Association of reported candidate monogenic genes with lung cancer risk</article-title><source>Clin Lung Cancer</source><year>2023</year><volume>24</volume><fpage>313</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1016/j.cllc.2023.01.005</pub-id><pub-id pub-id-type="pmid">36781323</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Rifkin AS, Less EM, Wei J, et al. Association of reported candidate monogenic genes with lung cancer risk. Clin Lung Cancer. 2023;24:313&#8211;21.<pub-id pub-id-type="pmid">36781323</pub-id><pub-id pub-id-type="doi">10.1016/j.cllc.2023.01.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H</given-names></name><name name-style="western"><surname>Bai</surname><given-names>J</given-names></name><etal/></person-group><article-title>Positive association of serum vitamin B6 levels with intrapulmonary lymph node and/or localized pleural metastases in non-small cell lung cancer: a retrospective study</article-title><source>Nutrients</source><year>2023</year><volume>15</volume><fpage>2340</fpage><pub-id pub-id-type="doi">10.3390/nu15102340</pub-id><pub-id pub-id-type="pmid">37242223</pub-id><pub-id pub-id-type="pmcid">PMC10223430</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Liu L, Yu H, Bai J, et al. Positive association of serum vitamin B6 levels with intrapulmonary lymph node and/or localized pleural metastases in non-small cell lung cancer: a retrospective study. Nutrients. 2023;15:2340.<pub-id pub-id-type="pmid">37242223</pub-id><pub-id pub-id-type="doi">10.3390/nu15102340</pub-id><pub-id pub-id-type="pmcid">PMC10223430</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Khoury</surname><given-names>T</given-names></name><etal/></person-group><article-title>Relationships of hHpr1/p84/Thoc1 expression to clinicopathologic characteristics and prognosis in non-small cell lung cancer</article-title><source>Ann Clin Lab Sci</source><year>2008</year><volume>38</volume><fpage>105</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">18469354</pub-id><pub-id pub-id-type="pmcid">PMC2606038</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Yang J, Li Y, Khoury T, et al. Relationships of hHpr1/p84/Thoc1 expression to clinicopathologic characteristics and prognosis in non-small cell lung cancer. Ann Clin Lab Sci. 2008;38:105&#8211;12.<pub-id pub-id-type="pmid">18469354</pub-id><pub-id pub-id-type="pmcid">PMC2606038</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>N</given-names></name><name name-style="western"><surname>Shao</surname><given-names>K</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><etal/></person-group><article-title>The impact of positive cancer family history on the clinical features and outcome of patients with non-small cell lung cancer</article-title><source>Fam Cancer</source><year>2011</year><volume>10</volume><fpage>331</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1007/s10689-010-9403-0</pub-id><pub-id pub-id-type="pmid">21104151</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Li N, Shao K, Chen Z, et al. The impact of positive cancer family history on the clinical features and outcome of patients with non-small cell lung cancer. Fam Cancer. 2011;10:331&#8211;6.<pub-id pub-id-type="pmid">21104151</pub-id><pub-id pub-id-type="doi">10.1007/s10689-010-9403-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Pan</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name><etal/></person-group><article-title>Expression of ERCC1 mRNA in non-small cell lung cancer tissues and survival analysis of patients</article-title><source>Life Sci J</source><year>2013</year><volume>10</volume><issue>2</issue><fpage>1926</fpage><lpage>1931</lpage></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Li X, Pan X, Wang P, et al. Expression of ERCC1 mRNA in non-small cell lung cancer tissues and survival analysis of patients. Life Sci J. 2013;10(2):1926&#8211;31.</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Xu</surname><given-names>F</given-names></name><etal/></person-group><article-title>DNA repair gene polymorphisms in relation to non-small cell lung cancer survival</article-title><source>Cell Physiol Biochem</source><year>2015</year><volume>36</volume><fpage>1419</fpage><lpage>1429</lpage><pub-id pub-id-type="doi">10.1159/000430307</pub-id><pub-id pub-id-type="pmid">26159902</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Su Y, Zhang H, Xu F, et al. DNA repair gene polymorphisms in relation to non-small cell lung cancer survival. Cell Physiol Biochem. 2015;36:1419&#8211;29.<pub-id pub-id-type="pmid">26159902</pub-id><pub-id pub-id-type="doi">10.1159/000430307</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cortellini</surname><given-names>A</given-names></name><name name-style="western"><surname>Giusti</surname><given-names>R</given-names></name><name name-style="western"><surname>Filetti</surname><given-names>M</given-names></name><etal/></person-group><article-title>High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status</article-title><source>J Hematol Oncol</source><year>2022</year><volume>15</volume><fpage>9</fpage><pub-id pub-id-type="doi">10.1186/s13045-022-01226-2</pub-id><pub-id pub-id-type="pmid">35062993</pub-id><pub-id pub-id-type="pmcid">PMC8780322</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Cortellini A, Giusti R, Filetti M, et al. High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. J Hematol Oncol. 2022;15:9.<pub-id pub-id-type="pmid">35062993</pub-id><pub-id pub-id-type="doi">10.1186/s13045-022-01226-2</pub-id><pub-id pub-id-type="pmcid">PMC8780322</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tefre</surname><given-names>T</given-names></name><name name-style="western"><surname>B&#248;rresen</surname><given-names>AL</given-names></name><name name-style="western"><surname>Aamdal</surname><given-names>S</given-names></name><etal/></person-group><article-title>Studies of the L-myc DNA polymorphism and relation to metastasis in Norwegian lung cancer patients</article-title><source>Br J Cancer</source><year>1990</year><volume>61</volume><fpage>809</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1038/bjc.1990.182</pub-id><pub-id pub-id-type="pmid">1973618</pub-id><pub-id pub-id-type="pmcid">PMC1971690</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Tefre T, B&#248;rresen AL, Aamdal S, et al. Studies of the L-myc DNA polymorphism and relation to metastasis in Norwegian lung cancer patients. Br J Cancer. 1990;61:809&#8211;12.<pub-id pub-id-type="pmid">1973618</pub-id><pub-id pub-id-type="doi">10.1038/bjc.1990.182</pub-id><pub-id pub-id-type="pmcid">PMC1971690</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Javid</surname><given-names>J</given-names></name><name name-style="western"><surname>Mir</surname><given-names>R</given-names></name><name name-style="western"><surname>Mirza</surname><given-names>M</given-names></name><etal/></person-group><article-title>CC genotype of anti-apoptotic gene BCL-2 (-938 C/A) is an independent prognostic marker of unfavorable clinical outcome in patients with non-small-cell lung cancer</article-title><source>Clin Transl Oncol</source><year>2015</year><volume>17</volume><fpage>289</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1007/s12094-014-1226-2</pub-id><pub-id pub-id-type="pmid">25257838</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Javid J, Mir R, Mirza M, et al. CC genotype of anti-apoptotic gene BCL-2 (-938 C/A) is an independent prognostic marker of unfavorable clinical outcome in patients with non-small-cell lung cancer. Clin Transl Oncol. 2015;17:289&#8211;95.<pub-id pub-id-type="pmid">25257838</pub-id><pub-id pub-id-type="doi">10.1007/s12094-014-1226-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kheradmand</surname><given-names>F</given-names></name><name name-style="western"><surname>Davis</surname><given-names>CF</given-names></name><etal/></person-group><article-title>Focused analysis of exome sequencing data for rare germline mutations in familial and sporadic lung cancer</article-title><source>J Thorac Oncol</source><year>2016</year><volume>11</volume><fpage>52</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2015.09.015</pub-id><pub-id pub-id-type="pmid">26762739</pub-id><pub-id pub-id-type="pmcid">PMC4714038</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Liu Y, Kheradmand F, Davis CF, et al. Focused analysis of exome sequencing data for rare germline mutations in familial and sporadic lung cancer. J Thorac Oncol. 2016;11:52&#8211;61.<pub-id pub-id-type="pmid">26762739</pub-id><pub-id pub-id-type="doi">10.1016/j.jtho.2015.09.015</pub-id><pub-id pub-id-type="pmcid">PMC4714038</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Lin</surname><given-names>D</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>Association between single nucleotide polymorphisms of NOTCH signaling pathway-related genes and the prognosis of NSCLC</article-title><source>Cancer Manag Res</source><year>2019</year><volume>11</volume><fpage>6895</fpage><lpage>6905</lpage><pub-id pub-id-type="doi">10.2147/CMAR.S197747</pub-id><pub-id pub-id-type="pmid">31413635</pub-id><pub-id pub-id-type="pmcid">PMC6662170</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Xu Q, Lin D, Li X, et al. Association between single nucleotide polymorphisms of NOTCH signaling pathway-related genes and the prognosis of NSCLC. Cancer Manag Res. 2019;11:6895&#8211;905.<pub-id pub-id-type="pmid">31413635</pub-id><pub-id pub-id-type="doi">10.2147/CMAR.S197747</pub-id><pub-id pub-id-type="pmcid">PMC6662170</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Suo</surname><given-names>P</given-names></name><etal/></person-group><article-title>The contribution of hereditary cancer-related germline mutations to lung cancer susceptibility</article-title><source>Transl Lung Cancer Res</source><year>2020</year><volume>9</volume><fpage>646</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.21037/tlcr-19-403</pub-id><pub-id pub-id-type="pmid">32676327</pub-id><pub-id pub-id-type="pmcid">PMC7354149</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Liu M, Liu X, Suo P, et al. The contribution of hereditary cancer-related germline mutations to lung cancer susceptibility. Transl Lung Cancer Res. 2020;9:646&#8211;58.<pub-id pub-id-type="pmid">32676327</pub-id><pub-id pub-id-type="doi">10.21037/tlcr-19-403</pub-id><pub-id pub-id-type="pmcid">PMC7354149</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suzuki</surname><given-names>K</given-names></name><name name-style="western"><surname>Ogura</surname><given-names>T</given-names></name><name name-style="western"><surname>Yokose</surname><given-names>T</given-names></name><etal/></person-group><article-title>Microsatellite instability in female non-small-cell lung cancer patients with familial clustering of malignancy</article-title><source>Br J Cancer</source><year>1998</year><volume>77</volume><fpage>1003</fpage><lpage>1008</lpage><pub-id pub-id-type="doi">10.1038/bjc.1998.165</pub-id><pub-id pub-id-type="pmid">9528848</pub-id><pub-id pub-id-type="pmcid">PMC2150104</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Suzuki K, Ogura T, Yokose T, et al. Microsatellite instability in female non-small-cell lung cancer patients with familial clustering of malignancy. Br J Cancer. 1998;77:1003&#8211;8.<pub-id pub-id-type="pmid">9528848</pub-id><pub-id pub-id-type="doi">10.1038/bjc.1998.165</pub-id><pub-id pub-id-type="pmcid">PMC2150104</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yilmaz</surname><given-names>A</given-names></name><name name-style="western"><surname>Mohamed</surname><given-names>N</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>KA</given-names></name><etal/></person-group><article-title>Clinical and metabolic parameters in non-small cell lung carcinoma and colorectal cancer patients with and without KRAS mutations</article-title><source>Int J Environ Res Public Health</source><year>2014</year><volume>11</volume><fpage>8645</fpage><lpage>8660</lpage><pub-id pub-id-type="doi">10.3390/ijerph110908645</pub-id><pub-id pub-id-type="pmid">25158139</pub-id><pub-id pub-id-type="pmcid">PMC4198984</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Yilmaz A, Mohamed N, Patterson KA, et al. Clinical and metabolic parameters in non-small cell lung carcinoma and colorectal cancer patients with and without KRAS mutations. Int J Environ Res Public Health. 2014;11:8645&#8211;60.<pub-id pub-id-type="pmid">25158139</pub-id><pub-id pub-id-type="doi">10.3390/ijerph110908645</pub-id><pub-id pub-id-type="pmcid">PMC4198984</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>P-C</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y-C</given-names></name></person-group><article-title>Correlation between familial cancer history and epidermal growth factor receptor mutations in Taiwanese never smokers with non-small cell lung cancer: a case-control study</article-title><source>J Thorac Dis</source><year>2015</year><volume>7</volume><fpage>281</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">25922704</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3978/j.issn.2072-1439.2015.02.03</pub-id><pub-id pub-id-type="pmcid">PMC4387390</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Cheng P-C, Cheng Y-C. Correlation between familial cancer history and epidermal growth factor receptor mutations in Taiwanese never smokers with non-small cell lung cancer: a case-control study. J Thorac Dis. 2015;7:281&#8211;7.<pub-id pub-id-type="pmid">25922704</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3978/j.issn.2072-1439.2015.02.03</pub-id><pub-id pub-id-type="pmcid">PMC4387390</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsu</surname><given-names>K-H</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>J-S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C-L</given-names></name><etal/></person-group><article-title>Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>53299</fpage><lpage>53308</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.10715</pub-id><pub-id pub-id-type="pmid">27449093</pub-id><pub-id pub-id-type="pmcid">PMC5288187</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Hsu K-H, Tseng J-S, Wang C-L, et al. Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients. Oncotarget. 2016;7:53299&#8211;308.<pub-id pub-id-type="pmid">27449093</pub-id><pub-id pub-id-type="doi">10.18632/oncotarget.10715</pub-id><pub-id pub-id-type="pmcid">PMC5288187</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><etal/></person-group><article-title>Concomitant genetic alterations are associated with plasma D-dimer level in patients with non-small-cell lung cancer</article-title><source>Future Oncol</source><year>2022</year><volume>18</volume><fpage>679</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.2217/fon-2021-0455</pub-id><pub-id pub-id-type="pmid">34789015</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Chang F, Zhang H, Chen C, et al. Concomitant genetic alterations are associated with plasma D-dimer level in patients with non-small-cell lung cancer. Future Oncol. 2022;18:679&#8211;90.<pub-id pub-id-type="pmid">34789015</pub-id><pub-id pub-id-type="doi">10.2217/fon-2021-0455</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ambrosone</surname><given-names>CB</given-names></name><name name-style="western"><surname>Rao</surname><given-names>U</given-names></name><name name-style="western"><surname>Michalek</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Lung cancer histologic types and family history of cancer. Analysis of histologic subtypes of 872 patients with primary lung cancer</article-title><source>Cancer</source><year>1993</year><volume>72</volume><fpage>1192</fpage><lpage>1198</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1097-0142(19930815)72:4&amp;#x0003c;1192::AID-CNCR2820720410&amp;#x0003e;3.0.CO;2-S</pub-id><pub-id pub-id-type="pmid">8393366</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Ambrosone CB, Rao U, Michalek AM, et al. Lung cancer histologic types and family history of cancer. Analysis of histologic subtypes of 872 patients with primary lung cancer. Cancer. 1993;72:1192&#8211;8.<pub-id pub-id-type="pmid">8393366</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1097-0142(19930815)72:4&amp;#x0003c;1192::AID-CNCR2820720410&amp;#x0003e;3.0.CO;2-S</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsuchiya</surname><given-names>M</given-names></name><name name-style="western"><surname>Iwasaki</surname><given-names>M</given-names></name><name name-style="western"><surname>Otani</surname><given-names>T</given-names></name><etal/></person-group><article-title>Breast cancer in first-degree relatives and risk of lung cancer: assessment of the existence of gene sex interactions</article-title><source>Jpn J Clin Oncol</source><year>2007</year><volume>37</volume><fpage>419</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1093/jjco/hym048</pub-id><pub-id pub-id-type="pmid">17586847</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Tsuchiya M, Iwasaki M, Otani T, et al. Breast cancer in first-degree relatives and risk of lung cancer: assessment of the existence of gene sex interactions. Jpn J Clin Oncol. 2007;37:419&#8211;23.<pub-id pub-id-type="pmid">17586847</pub-id><pub-id pub-id-type="doi">10.1093/jjco/hym048</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banik</surname><given-names>A</given-names></name><name name-style="western"><surname>Schwarzer</surname><given-names>R</given-names></name><name name-style="western"><surname>Pawlowska</surname><given-names>I</given-names></name><etal/></person-group><article-title>Women with family cancer history are at risk for poorer physical quality of life and lower self-efficacy: a longitudinal study among men and women with non-small cell lung cancer</article-title><source>Health Qual Life Outcomes</source><year>2017</year><volume>15</volume><fpage>62</fpage><pub-id pub-id-type="doi">10.1186/s12955-017-0645-5</pub-id><pub-id pub-id-type="pmid">28376887</pub-id><pub-id pub-id-type="pmcid">PMC5381144</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Banik A, Schwarzer R, Pawlowska I, et al. Women with family cancer history are at risk for poorer physical quality of life and lower self-efficacy: a longitudinal study among men and women with non-small cell lung cancer. Health Qual Life Outcomes. 2017;15:62.<pub-id pub-id-type="pmid">28376887</pub-id><pub-id pub-id-type="doi">10.1186/s12955-017-0645-5</pub-id><pub-id pub-id-type="pmcid">PMC5381144</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>P-H</given-names></name><name name-style="western"><surname>Chuang</surname><given-names>J-H</given-names></name><name name-style="western"><surname>Lu</surname><given-names>T-P</given-names></name><etal/></person-group><article-title>Non-intubated versus intubated video-assisted thoracic surgery in patients aged 75 years and older: a propensity matching study</article-title><source>Front Surg</source><year>2022</year><volume>9</volume><fpage>880007</fpage><pub-id pub-id-type="doi">10.3389/fsurg.2022.880007</pub-id><pub-id pub-id-type="pmid">35586501</pub-id><pub-id pub-id-type="pmcid">PMC9108723</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Chen P-H, Chuang J-H, Lu T-P, et al. Non-intubated versus intubated video-assisted thoracic surgery in patients aged 75 years and older: a propensity matching study. Front Surg. 2022;9: 880007.<pub-id pub-id-type="pmid">35586501</pub-id><pub-id pub-id-type="doi">10.3389/fsurg.2022.880007</pub-id><pub-id pub-id-type="pmcid">PMC9108723</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Pulmonary mucoepidermoid carcinoma in the Chinese population: a clinical characteristic and prognostic analysis</article-title><source>Front Oncol</source><year>2022</year><volume>12</volume><fpage>916906</fpage><pub-id pub-id-type="doi">10.3389/fonc.2022.916906</pub-id><pub-id pub-id-type="pmid">36119481</pub-id><pub-id pub-id-type="pmcid">PMC9476550</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Li Q, Wei X, Wang Y, et al. Pulmonary mucoepidermoid carcinoma in the Chinese population: a clinical characteristic and prognostic analysis. Front Oncol. 2022;12: 916906.<pub-id pub-id-type="pmid">36119481</pub-id><pub-id pub-id-type="doi">10.3389/fonc.2022.916906</pub-id><pub-id pub-id-type="pmcid">PMC9476550</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parsons</surname><given-names>DW</given-names></name><name name-style="western"><surname>Roy</surname><given-names>A</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Diagnostic yield of clinical tumor and germline whole-exome sequencing for children with solid tumors</article-title><source>JAMA Oncol</source><year>2016</year><volume>2</volume><fpage>616</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2015.5699</pub-id><pub-id pub-id-type="pmid">26822237</pub-id><pub-id pub-id-type="pmcid">PMC5471125</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Parsons DW, Roy A, Yang Y, et al. Diagnostic yield of clinical tumor and germline whole-exome sequencing for children with solid tumors. JAMA Oncol. 2016;2:616&#8211;24.<pub-id pub-id-type="pmid">26822237</pub-id><pub-id pub-id-type="doi">10.1001/jamaoncol.2015.5699</pub-id><pub-id pub-id-type="pmcid">PMC5471125</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dwivedi</surname><given-names>S</given-names></name><name name-style="western"><surname>Pathak</surname><given-names>R</given-names></name><name name-style="western"><surname>Agarwalla</surname><given-names>R</given-names></name><etal/></person-group><article-title>The intergenerational transmission of tobacco habit: role of parents and the family</article-title><source>J Family Med Prim Care</source><year>2016</year><volume>5</volume><fpage>373</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.4103/2249-4863.192379</pub-id><pub-id pub-id-type="pmid">27843844</pub-id><pub-id pub-id-type="pmcid">PMC5084564</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Dwivedi S, Pathak R, Agarwalla R, et al. The intergenerational transmission of tobacco habit: role of parents and the family. J Family Med Prim Care. 2016;5:373&#8211;7.<pub-id pub-id-type="pmid">27843844</pub-id><pub-id pub-id-type="doi">10.4103/2249-4863.192379</pub-id><pub-id pub-id-type="pmcid">PMC5084564</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saari</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Kentala</surname><given-names>J</given-names></name><name name-style="western"><surname>Mattila</surname><given-names>KJ</given-names></name></person-group><article-title>The smoking habit of a close friend or family member&#8211;how deep is the impact? A cross-sectional study</article-title><source>BMJ Open</source><year>2014</year><volume>4</volume><fpage>e003218</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2013-003218</pub-id><pub-id pub-id-type="pmid">24549158</pub-id><pub-id pub-id-type="pmcid">PMC3931984</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Saari AJ, Kentala J, Mattila KJ. The smoking habit of a close friend or family member&#8211;how deep is the impact? A cross-sectional study. BMJ Open. 2014;4: e003218.<pub-id pub-id-type="pmid">24549158</pub-id><pub-id pub-id-type="doi">10.1136/bmjopen-2013-003218</pub-id><pub-id pub-id-type="pmcid">PMC3931984</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bougeard</surname><given-names>G</given-names></name><name name-style="western"><surname>Renaux-Petel</surname><given-names>M</given-names></name><name name-style="western"><surname>Flaman</surname><given-names>J-M</given-names></name><etal/></person-group><article-title>Revisiting Li-Fraumeni Syndrome from TP53 mutation carriers</article-title><source>J Clin Oncol</source><year>2015</year><volume>33</volume><fpage>2345</fpage><lpage>2352</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.59.5728</pub-id><pub-id pub-id-type="pmid">26014290</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Bougeard G, Renaux-Petel M, Flaman J-M, et al. Revisiting Li-Fraumeni Syndrome from TP53 mutation carriers. J Clin Oncol. 2015;33:2345&#8211;52.<pub-id pub-id-type="pmid">26014290</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2014.59.5728</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oxnard</surname><given-names>GR</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R</given-names></name><name name-style="western"><surname>Pharr</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Germline EGFR mutations and familial lung cancer</article-title><source>J Clin Oncol</source><year>2023</year><volume>41</volume><fpage>5274</fpage><lpage>5284</lpage><pub-id pub-id-type="doi">10.1200/JCO.23.01372</pub-id><pub-id pub-id-type="pmid">37579253</pub-id><pub-id pub-id-type="pmcid">PMC12153668</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Oxnard GR, Chen R, Pharr JC, et al. Germline EGFR mutations and familial lung cancer. J Clin Oncol. 2023;41:5274&#8211;84.<pub-id pub-id-type="pmid">37579253</pub-id><pub-id pub-id-type="doi">10.1200/JCO.23.01372</pub-id><pub-id pub-id-type="pmcid">PMC12153668</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><mixed-citation publication-type="other">van der Leest C, Wagner A, Pedrosa RM, et al: Novel EGFR V834L Germline Mutation Associated With Familial Lung Adenocarcinoma. JCO Precis Oncol 2:PO.17.00266, 2018<pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/PO.17.00266</pub-id><pub-id pub-id-type="pmcid">PMC7446426</pub-id><pub-id pub-id-type="pmid">32913987</pub-id></mixed-citation></ref><ref id="CR74"><label>74.</label><mixed-citation publication-type="other">Ohtsuka K, Ohnishi H, Fujiwara M, et al: Predisposition to Lung Adenocarcinoma in a Family Harboring the Germline EGFR V843I Mutation. JCO Precis Oncol 3:PO.19.00104, 2019<pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/PO.19.00104</pub-id><pub-id pub-id-type="pmcid">PMC7446308</pub-id><pub-id pub-id-type="pmid">32914005</pub-id></mixed-citation></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Chu</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Susceptibility genes associated with multiple primary cancers</article-title><source>Cancers</source><year>2023</year><volume>15</volume><fpage>5788</fpage><pub-id pub-id-type="doi">10.3390/cancers15245788</pub-id><pub-id pub-id-type="pmid">38136334</pub-id><pub-id pub-id-type="pmcid">PMC10741435</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Lu M, Zhang X, Chu Q, et al. Susceptibility genes associated with multiple primary cancers. Cancers. 2023;15:5788.<pub-id pub-id-type="pmid">38136334</pub-id><pub-id pub-id-type="doi">10.3390/cancers15245788</pub-id><pub-id pub-id-type="pmcid">PMC10741435</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Passiglia</surname><given-names>F</given-names></name><name name-style="western"><surname>Cinquini</surname><given-names>M</given-names></name><name name-style="western"><surname>Bertolaccini</surname><given-names>L</given-names></name><etal/></person-group><article-title>Benefits and harms of lung cancer screening by chest computed tomography: a systematic review and meta-analysis</article-title><source>J Clin Oncol</source><year>2021</year><volume>39</volume><fpage>2574</fpage><lpage>2585</lpage><pub-id pub-id-type="doi">10.1200/JCO.20.02574</pub-id><pub-id pub-id-type="pmid">34236916</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Passiglia F, Cinquini M, Bertolaccini L, et al. Benefits and harms of lung cancer screening by chest computed tomography: a systematic review and meta-analysis. J Clin Oncol. 2021;39:2574&#8211;85.<pub-id pub-id-type="pmid">34236916</pub-id><pub-id pub-id-type="doi">10.1200/JCO.20.02574</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Triphuridet</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>SS</given-names></name><name name-style="western"><surname>Nagasaka</surname><given-names>M</given-names></name><etal/></person-group><article-title>Low-dose computed tomography (LDCT) lung cancer screening in asian female never-smokers is as efficacious in detecting lung cancer as in Asian male ever-smokers: a systematic review and meta-analysis</article-title><source>J Thorac Oncol</source><year>2023</year><volume>18</volume><fpage>698</fpage><lpage>717</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2023.01.094</pub-id><pub-id pub-id-type="pmid">36775191</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Triphuridet N, Zhang SS, Nagasaka M, et al. Low-dose computed tomography (LDCT) lung cancer screening in asian female never-smokers is as efficacious in detecting lung cancer as in Asian male ever-smokers: a systematic review and meta-analysis. J Thorac Oncol. 2023;18:698&#8211;717.<pub-id pub-id-type="pmid">36775191</pub-id><pub-id pub-id-type="doi">10.1016/j.jtho.2023.01.094</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>